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ABSTRACT 
 
INTRODUCTION 
Pancreatic Neuroendocrine Tumours (PNETS) are a heterogeneous group of tumours 
originating in the pancreatic islet cells.  The last three decades have seen an increase in 
incidence which, according to Surveillance, Epidemiology and End-Result (SEER) data is 
reported to be 0.43/100,000 person-years. Treatment options currently include surgery as 
well as a range of locoregional and systemic therapies.  Despite this, the prognosis of this 
disease remains poor and biomarkers that accurately predict the clinical behavior of these 
tumours are lacking. Over the past decade, dysregulation of microRNAs (miRNAs), short 
non-coding RNAs ~17-25 nucleotides in length, have been shown to play an important role in 
the development of many cancers through their post-transcriptional regulation of gene 
expression. Few studies to date, however, have investigated the role of miRNAs as diagnostic 
or prognostic markers in PNETs. 
 
 
METHODS 
All patients undergoing surgical resection of PNETs at Royal North Shore Hospital and 
North Shore Private Hospitals (Sydney, Australia) between 1992 and 2014 were considered 
eligible for retrospective study inclusion. Patients were divided into two groups based on 
whether their disease was locoregional only (L) or whether they had distant metastases either 
at the time of surgery or during their postoperative follow-up (DM). Clinicopathological data 
was retrospectively collated from a prospectively maintained database. All patients had 
resection with curative intent including enucleation (insulinoma only), pancreatic resection 
+/- regional lymph node clearance +/- limited liver resection for isolated metastasis. 
 
RNA was extracted from formalin-fixed, paraffin embedded PNET samples and microarray 
analysis performed. MicroRNAs with statistically significant differential expression between 
patients with locoregional disease only versus those who developed metastases were subject 
to in-silico analysis using three target prediction databases in search of gene targets that have 
previously been implicated in PNET pathogenesis. 
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RESULTS 
37 patients (19 females and 18 males) were included in the study. Of these patients, 23 had 
locoregional disease only. Four patients had solitary liver metastases at initial presentation 
while ten developed distant metastases during the course of their follow-up. Patient subgroup 
DM had poorer overall survival (OS) as compared to subgroup L (p = 0.046). 506 miRNAs 
with differential expression between the ‘Distant metastasis’ group and ‘Locoregional’ group 
were identified. Of these, 265 miRNAs were downregulated, whilst 241 were upregulated. Of 
these, four miRNAs were differentially expressed to statistical significance. These included 
miR-3653 which was upregulated and miR-4417, miR-574-3p and miR-664b-3p which were 
all downregulated. Only miRNA-3653 was identified by all three databases as having a 
potential PNET-related target; ATRX. 
 
 
CONCLUSION 
Higher expression of tumour miR-3653 was seen in the group of patients with metastatic 
disease compared to those with only locoregional disease.  Several bioinformatic tools 
predicted transcriptional regulator ATRX as a possible target for miR-3653. Thus, it is 
possible that miR-3653 could potentially be a biomarker for metastatic potential and 
consequently poorer prognosis in patients with PNETs, although these conclusions cannot be 
made with certainty given the limitations of this study and further work beginning with 
validation is required. 
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1. INTRODUCTION 
 
1.1 PANCREATIC NEUROENDOCRINE TUMOURS GENERALLY 
 
Pancreatic neuroendocrine tumours (PNETs) comprise a group of tumours arising from islet 
cells of the pancreas. As with other types of neuroendocrine tumours (NETs) which were 
originally described as carcinoid (or “Karzinoid”) by Siegried Oberdorfer [1] in 1907, they 
arise from cells of the diffuse neuroendocrine system, with possible but unproven embryonic 
neural crest origin [2]. They are characterised by the expression of somatostatin receptors and 
neuroendocrine markers such as chromogranin A (CgA), synaptophysin and neuron-specific 
enolase (NSE)[3-5]. 
 
 
1.1.1 EPIDEMIOLOGY 
 
PNETs account for <5% of primary pancreatic tumours; much less common than their 
exocrine tumour counterparts [6, 7].  Recent data from the Surveillance, Epidemiology and 
End-Result (SEER) Program have reported the incidence of PNETs to be 0.43/100,000 
person-years. The last three decades however, have seen a significant rise in their incidence 
(SEER data reported the incidence to be 0.17/100,000 person-years in 1970)[8]. This may be 
due in part to improved diagnostics, recognition and the relatively indolent nature of this 
disease entity [4].  The incidence of PNETs reported in autopsy studies has varied 
significantly; from 0.07% up to 10%, inferring that there is a proportion of these tumours that 
remain undiagnosed, most likely as consequence of their clinical silence [9, 10]. 
 
 
1.1.1.1 Age, sex and ethnic distributions 
 
PNETs can occur at any age, however they most frequently occur between the ages of 30 and 
50 years [11]. While the most studies have reported that they occur in males and females 
more or less equally [12], it has been reported that insulinomas and VIP-omas exhibit a slight 
female predominance [13, 14], whereas gastrinomas predominate slightly in males [4]. No 
clear difference in PNET occurrence by race has been reported to date [4]. 
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1.1.1.3 Syndrome-associated PNETs 
 
While the majority of PNETs occur sporadically, approximately 10-15% occur as part of 
syndromes inherited in an autosomal dominant pattern, such as multiple endocrine neoplasia 
(MEN1), Von Hippel-Lindau syndrome (VHL), neurofibromatosis type 1 (NF1) and tuberous 
sclerosis complex (TSC) [15]. Typically, syndrome-associated or familial PNETs exhibit a 
more indolent course and in most cases a more favourable prognosis than sporadic PNETs 
[16]. The individual genetic syndromes are discussed in more detail in section 1.15 below. 
 
 
1.1.2 FUNCTIONAL VERSUS NON-FUNCTIONAL PNETS 
 
PNETs are classified as either functional or non-functional based whether the hormones they 
produce result in a clinically-detectable syndrome.  Historically, the literature reported that 
functional PNETs (F-PNETs) predominated, however more recent publications have 
disagreed, reporting that the majority of PNETs in clinical series, from 50-75% in fact, are 
non-functional PNETs (NF-PNETs) [3, 17-25].  Both functioning and non-functioning 
PNETs can be either benign or malignant in nature [26].  
 
 
1.1.2.1 Non-functional PNETs 
 
Although they are not associated with a clinical syndrome, NF-PNETs produce certain 
polypeptides such as NSE, pancreatic polypeptide (PP), ghrelin, neurotensin, motilin and 
chromogranins; the latter playing an important role in detection of disease, providing an 
indication of tumour burden, and, in the setting of surveillance, aiding in the identification of 
disease recurrence or progression. Since they do not produce symptoms as a consequence of 
hormone excess, NF-PNETs are often not detected until they grow to a size at which they 
exert a mass effect on surrounding structures or, indeed, metastasise [27].  Consequently, 
they generally present at a more advanced stage than F-PNETs, with up to 80% of NF-
PNETS presenting with hepatic metastases [3, 21].  
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1.1.2.2 Functional PNETs 
 
Representing the minority of PNETs, F-PNETs are associated with excess hormone secretion 
resulting in a constellation of specific clinical symptoms.  Of these tumours, insulinomas are 
the most common, followed by gastrinomas, glucagonomas, VIPomas and somatostatinomas 
[28]. Clinical presentations of the various functional subtypes are discussed in more detail in 
section 1.1.6.2 below. 
 
 
1.1.3 RISK FACTORS  
 
1.1.3.1 PNETs associated with inherited syndromes 
 
As previously mentioned, PNETs can occur either in the context of an inherited disorder or 
sporadically.  Inherited syndromes are discussed in further detail in section 1.1.5 below. 
 
 
1.1.3.2 Risk factors for sporadic PNETs 
 
While familial PNETs are associated with relatively well-defined inherited syndromes, there 
is little data on risk factors for sporadic PNETs.  Some studies to date have suggested family 
history of any cancer (in a first degree relative), socioeconomic status, alcohol intake, body 
mass index, chronic pancreatitis and type II Diabetes Mellitus as possible risk factors [29-34], 
although cause and effect has not been demonstrated. 
 
In a recently published study, Ben et al examined risk factors for sporadic PNETs in 385 
patients of the Han Chinese ethnic group compared to 614 sex and age matched controls. For 
NF-PNETs, they identified ‘ever’ or ‘heavy smoking’ category, a history of diabetes and a 
family history of any cancer in a first-degree relative as being independent risk factors [35].  
Alcohol intake was not identified as an independent risk factor, contradicting findings from 
previously published studies [32, 35]. For F-PNETs for instance, alcohol intake greater than 
or equal to 30 grams per day was previously identified as an independent risk factor for 
PNET development by Zhan et al [33]. 
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1.1.4 GENETICS AND PATHOGENESIS 
 
Studies on the pathogenesis of both syndrome-associated (i.e. those associated with MEN1, 
VHL, NF1 or TSC) and sporadic PNETs (resulting from somatic mutations) have postulated 
that pluripotent stem cells of the endocrine pancreas pass through a sequence of stages from 
initial hyperplasia to the development of neoplasia [36, 37].  It is thought that they form 
accumulations with both endocrine and exocrine phenotypes [38].  
 
While these syndrome-associated pathogenetic mechanisms are somewhat known, the 
mechanisms by which sporadic PNETs develop are still poorly understood. Emerging 
evidence has implicated the menin, alpha-thalassaemia/mental retardation syndrome X-linked 
(ATRX) and death-associated protein 6 (DAXX) genes in the tumorigenesis of 
predominantly low- to intermediate-grade sporadic PNETs [39]. The absence of these 
mutations has been associated with a poorer prognosis [39].  Mutations in Tuberous Sclerosis 
Complex 2 (TSC2) and phosphatase and tensin homolog (PTEN) have also been found to 
play a role in the tumorigenesis of well-differentiated PNETs [40, 41]. For poorly-
differentiated neuroendocrine carcinomas, Retinoblastoma 1 (RB1) and TP53 mutations have 
been identified[41]. 
 
Mutations in MEN1, DAXX/ATRX complex and mammalian target of Rapamycin (mTOR) 
genes occur in 44%, 43% and 15% of patients respectively and are thought to be ‘driver’ 
mutations for the development of PNETs [42] MEN1, for example, functions as a tumour 
suppressor gene (TSG). Loss of function can be either inherited or sporadic and is discussed 
in further detail in section 1.1.5.1. 
 
DAXX and ATRX function together (by forming a dimer) and play a role in the stabilisation 
and remodeling of chromatin.  More specifically, they are associate with abnormal telomeres 
in a telomerase-independent telomere maintenance mechanism known as ALT (alternative 
lengthening of telomeres)[43]. 
 
The mTOR pathway plays a role in cell proliferation and survival [39].  Mutations resulting 
in abnormal activation of the mTOR pathway (including TCS2, PTEN and PIK3CA) have 
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been described in patients with PNETs. These mutations, along with the more rare 
VEGF/VHL mutations are associated with a poorer prognosis [39]. 
 
Finally, hypermethylation of tumour suppressor genes are also thought to result in PNET 
formation. In their 2003 study, House et al described RASSF1A, p16/INK4A and O6-MGMT 
genes as being silenced in 75%, 40% and 40% of patients with PNETs respectively [44]. 
 
 
1.1.5 FAMILIAL SYNDROMES 
 
1.1.5.1 Multiple Endocrine Neoplasia Type 1 (MEN1) 
 
It has been reported that 80-100% of patients with MEN1 will develop a PNET during their 
lifetime [45]. This autosomally-dominant endocrinopathy results from a mutation of the 
MEN1 gene and has an estimated prevalence of two per 100,000 [46]. The MEN1 gene 
implicated in the pathogenesis of this disease is located on the long arm of chromosome 11 
(11q13) and encodes the menin protein [47]. Over 1000 MEN1 mutations have been 
described to date [48]. The exact mechanism by which inactivation of this gene results in 
impaired tumour suppression/tumorigenesis has not been elucidated [49] but the syndrome is 
characterised by pituitary, parathyroid and pancreatic tumours.  Furthermore, it is associated 
with an increased predisposition for developing duodenal gastrinomas, adrenal adenomas, 
angiofibromas and lipomas [50].  PNETs are the most significant cause of disease-specific 
mortality in patients with MEN1, accounting for an estimated 40% of cases [51].  The 
average age of death in these patients has been reported at 55 years; younger than patients 
with PNETs in the absence of MEN1 syndrome [51].  The majority of the PNETs in MEN1 
patients are non-functioning microadenomas (<0.5cm in size) and the disease is typically 
multifocal.  Less than 15% of these NF-PNETs will grow to the point of becoming 
symptomatic [52-54]. 
 
Functioning PNETs have been reported in 20-70% of patients with MEN1.  Of these patients, 
approximately half will present with gastrinomas, 20% with insulinomas [48, 52, 55] and a 
small proportion will have glucagonomas, VIPomas and somatostatinomas [54]. 
 
 
	   16	  
1.1.5.2 Von Hippel Lindau Syndrome (VHL) 
 
Approximately 20% of patients with VHL will develop a PNET over the course of their life 
[45], almost all of which are non-functioning and solitary in nature [55]. The syndrome 
encompasses a variety of malignancies including central nervous system haemangiomas, 
phaeochromocytomas, retinal haemangioblastomas as well as serous cystadenomas and 
PNETs [50].  The Von Hippel Lindau gene, codes for a protein, pVHL which has a tumour 
suppressor function, playing a role in protein targeting for degradation and extracellular 
matrix regulation [56]. For the syndrome to develop there must be an inherited mutation of 
one allele (rendering it inactive), coupled with a somatic mutation, deletion or promotor 
hypermethylation of the second allele [56]. Mean age of diagnosis is approximately 29-38 
years [55]. 
 
 
1.1.5.3 Neurofibromatosis Type 1 (NF1) 
 
Also known as von Recklinghausen disease, Neurofibromatosis type 1 is one of three distinct 
forms of neurofibromatosis.  This autosomal dominant disorder affects around one in 3000 
individuals [57]. It is estimated that half of these cases result from inherited mutations, whilst 
the other half are the consequence of sporadic mutations.  They affect the NF1 gene (located 
at chromosome 17q11.2) which codes for neurofibromin, a guanine triphosphate hydrolase 
(GTPase)-activating protein that is thought to stimulated GTPase activity in the ras p21 
family [58-61].  Mutations have complete penetrance, however there is great variation in the 
clinical manifestations and their severity [61].  PNETs are seen in up to 10% of patients with 
NF1 [59]. 
 
 
1.1.5.4 Tuberous Sclerosis Complex (TSC) 
 
This rare multisystem disease affects approximately one in every 5,000-10,000 individuals 
[62-66], and results from a mutation of either the TSC1 or TSC2 gene.  Clinical 
manifestations primarily include widespread tumour development; lesions can occur in the 
central nervous system, kidneys, lungs, heart, skin and eyes.  The lifetime incidence of PNET 
in these patients is estimated to be approximately one percent [67]. 
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Syndrome Gene location Protein Clinical Features 
Multiple Endocrine 
Neoplasia 1 (MEN1) 
11q13 menin •  Primary hyperparathyroidism 
•  Pituitary tumours 
•  Adrenocortical tumours 
•  Carcinoid tumours 
•  Non-medullary thyroid 
tumours 
Von Hippel-Lindau 
Disease (VHL) 
3p25.5 VHL •  Phaeochromocytomas 
•  Retinal haemangioblastomas 
•  Cerebellar 
haemangioblastomas 
•  Renal cell carcinoma 
Neurofibromatosis 1 
(NF1) 
17q11.2 neurofibromin •  Neurofibromas 
•  Café au lait spots 
•  Phaeochromocytomas 
Tuberous Sclerosis 
Complex (TSC) 
9q34 (TSC1) 
16p13.3(TSC2) 
hamartin, 
tuberin 
•  Renal cysts 
•  Angiolipomas 
•  Cardiac rhabdomyomas 
 
Table 1: Familial syndromes associated with PNETs and their clinical manifestations 
[50, 56, 61, 62, 68] 
 
 
1.1.6 CLINICAL FEATURES 
 
1.1.6.1 Non-Functional PNETs 
 
Unlike functional PNETs that present with a constellation of symptoms dependent on the 
hormone being produced in excess, if not incidentally detected, NF-PNETs present with 
symptoms either as a result of mass effect or metastases, the most common site for the latter 
being the liver.  Patients can present with vague symptoms not too dissimilar from those 
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associated with pancreatic adenocarcinoma, such as abdominal pain, nausea, anorexia, weight 
loss, obstructive jaundice, recurrent pancreatitis and in some cases, a palpable abdominal 
mass on examination [27, 69-72].  They can also present with complications from metastatic 
disease, such as gastrointestinal bleeding, superior mesenteric vein and portal vein occlusion 
[73].   
 
 
1.1.6.2 Functional PNETs 
 
These PNETs present with well-defined clinical syndromes resulting from hypersecretion of 
hormones. The various subtypes of F-PNETs are described below: 
 
 
1.1.6.2.1 Insulinomas 
 
The most commonly-occurring F-PNET, these tumours usually present with symptoms of 
episodic hypoglycaemia. In up to 90% of cases, patients will exhibit the ‘Whipple triad’ at 
the time of diagnosis; plasma glucose level of < 50 mg/dL and symptoms of 
neuroglycopaenia (confusion, visual disturbance, diaphoresis, tremulousness) which are 
reversed after the administration of glucose [74, 75]. It has been reported that insulinomas 
occur predominately in the fifth decade of life and exhibit a higher incidence in females [74]. 
 
 
1.1.6.2.2 Gastrinomas 
 
The second most frequent type of F-PNET [20, 22], gastrinomas present with excess 
secretion of gastrin or Zollinger-Ellison Syndrome.  Manifestations include peptic ulcer 
disease, reflux and secretory diarrhoea [76]. 
 
 
1.1.6.2.3 Glucagonomas 
 
Tumours producing excess glucagon can result in necrolytic migratory erythema (present in 
about 52% at time of diagnosis) [77], cheilitis, diabetes mellitus (in approximately 20% of 
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patients at diagnosis [77]), anaemia, weight loss, diarrhoea, venous thrombosis and 
neuropsychiatric symptoms [78]. 
 
 
1.1.6.2.3 VIP-omas 
 
Patients with these tumours present with large volume watery secretory diarrhoea, which is 
associated with hypokalaemia and hypochlorydia.  Flushing and electrolyte abnormalities 
(hyperglycaemia, hypercalcaemia) can also result [79, 80]. 
 
 
1.1.5.2.4 Somatostatinomas 
 
These comprise a very small portion of functioning PNETs (<5%).  Only rarely do patients 
exhibit all symptoms, which include diabetes mellitus, diarrhoea or steatorrhoea, weight loss 
and gallbladder disease. In many instances, the diagnosis is made retrospectively, after 
immunohistochemical staining of the tumour specimen is correlated with patient symptoms 
[79, 81].   
 
 
1.1.7 DIAGNOSIS 
 
The heterogeneity of PNETs means that the diagnostic approach varies according to the 
clinical presentation. 
 
1.1.7.1 Serum markers for the diagnosis of NF-PNETs 
 
Although they are associated with an absence of symptoms from hormone hypersecretion, 
NF-PNETs often secrete hormones that are detectable in serum.  Most notable are the 
peptides chromogranin A (CgA) and pancreatic polypeptide (PP). Chromogranin A level 
correlates with the number of dense core secretory vesicles in neuroendocrine cells and is 
elevated in approximately 70% of patients with NF-PNETS.  Plasma levels are thought to 
indicate disease burden and diagnostic sensitivity is thought to be better in patients with 
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metastatic disease compared with localised disease (60-100% versus 29-50% respectively) 
[82-85]. 
 
Another biomarker for NF-PNETs, pancreatic polypeptide is produced by 50-70% of tumours 
[45, 83, 86-90].  On it’s own, its diagnostic sensitivity and specificity are relatively low [90, 
91], with one study reporting figures of 63% and 81% respectively from a study involving 
predominately NF-PNETs. 
 
As both serum CgA and PP can be elevated for a variety of unrelated reasons (including the 
use of proton pump inhibitors in the case of elevated CgA), an isolated elevation in either  
[90] marker alone is not diagnostic.  If both serum markers are elevated, however, the 
sensitivity for detecting a PNET reaches around 94% [83]. The diagnosis  of an NF-PNET is 
made upon the basis of serum levels of neuroendocrine biomarkers CgA and PP, cross-
sectional imaging as well as histological evidence [27].  Positive immunohistochemical 
staining for CgA and synaptophysin in tissue specimens is used to establish the diagnosis 
[92]. 
 
 
1.1.7.2 Serum markers for the diagnosis of functional PNETs 
 
While F-PNETs also result in elevated levels of CgA, it is usually the specific hormone 
secreted to excess (eg. insulin in insulinomas) that serves as a specific tumour marker in these 
instances. 
 
 
1.1.7.3 Imaging studies 
 
1.1.7.3.1 Computerised tomography (CT) 
 
Multiphasic computerised tomography (CT) with intravenous contrast administration is the 
most common initial imaging technique used for the evaluation of PNETs [93] having a > 
80% sensitivity for tumours >2cm in size [94].  As NF-PNETs are generally larger at time of 
diagnosis, contrast-enhanced CT is the imaging modality of choice for their detection, having 
a sensitivity of almost 100% [95-97].  Being highly vascular, PNETs are seen on CT as 
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hyperdense lesions.  Most lesions are very vascular, enhancing in the early arterial phase (20-
30 seconds post injection of iodinated contrast).  Washout occurs during the portal venous 
phase (60-70 seconds after contrast is administered) [98]. Thin slices obtained during both 
these phases [92] enable assessment of the lesion, surrounding tissue and associated 
vasculature whist maximising the ability to detect and evaluate hepatic metastases, which can 
appear isodense with liver tissue in the absence of contrast [93, 98-100].  The main 
limitations of CT are in the detection of smaller lesions <2 cm in size or insulinomas, where 
the sensitivity for detection decreases.  In these cases, endoscopic ultrasound (EUS) is often 
the imaging modality of choice [100]. 
 
 
1.1.7.3.2 Magnetic resonance imaging 
 
Magnetic resonance imaging (MRI) is also utilised in the assessment of primary PNETs and 
associated metastases.  Several small series have demonstrated a relatively higher sensitivity 
for the detection of liver metastases and tumour localisation using MRI compared to CT. 
Although, as with CT, sensitivity is limited by the size of the lesion [95, 101]. PNETs 
typically exhibit low signal intensity on T1-weighted imaging and high signal intensity on 
T2-weighted imaging [102-104].  Gadolinium contrast injection is used for the detection of 
small, hypervascular hepatic metastases [94]. 
 
 
1.1.7.3.3 Endoscopic ultrasound 
 
Endoscopic ultrasound (EUS) provides a high-resolution view of the pancreas and is 
therefore an ideal option for the detection of smaller, intra-pancreatic PNETs, detecting 90% 
of these tumours, including those as small as 2-3mm in diameter [45, 105].  In their 
systematic review of 612 patients from 17 cohort studies, James et al reported that EUS 
allowed for the detection of 28% of PNETs in instances where they were not detected on CT 
[106].  It also allows assessment of the lesion in relation to the main pancreatic duct, a crucial 
factor in determining the most appropriate operative intervention [92].  If coupled with fine-
needle aspiration (FNA), it can provide histological confirmation of diagnosis, while also 
providing an opportunity to tattoo small lesions for subsequent intraoperative localisation 
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[107].  In the case of insulinomas, which can often be multifocal and lack somatostatin 
receptors so are not easily detected with nuclear imaging, EUS is particularly useful.  
 
EUS is also utilised in the surveillance of patients with diffuse intrapancreatic disease not 
amenable to resection, as is sometimes seen  in MEN1 and VHL [92]. The main limitations 
of this modality are the fact that it is highly operator dependent and variable consistency in 
satisfactorily imaging the tail of the pancreas.  Furthermore, in rare instances, case reports of 
successful EUS-guided ablation of insulinomas using ethanol injection have been published 
[108]. The sensitivity for PNET detection by EUS reported in the literature ranges from 82-
93%, while specificity has been reported as ranging from 92-95% [105, 106, 109]. 
 
 
1.1.7.3.4 Nuclear imaging 
 
The over-expression of somatostatin receptors, particularly receptor two (SSTR2) in PNETs, 
has allowed for use of nuclear imaging to help characterise tumour location in a precise 
manner. 
 
111Indium-DTPA-octreotide SPECT (Octreoscan) has been used for staging, monitoring and 
selection of patients for peptide receptor radionuclide therapy (PRRT). Sensitivity and 
specificity for PNET detection has previously been reported as 90% and 80% respectively 
[110] and is particularly useful for the imaging of gastrinomas, glucagonomas and NF-
PNETs [107, 111-115]. It is less useful in imaging of insulinomas and poorly differentiated 
NETs which may express lower levels of SSTR [113, 115]. 
 
In centres where 68Gallium-based Positron Emission Tomography (PET) has become 
available, this has superseded Octreoscan in most circumstances due to its higher spatial 
resolution and lower cost. 68Gallium-DOTATOC and 68Gallium-DOTATATE PET scans 
have been demonstrated to have superior sensitivity and specificity than Octreoscan, and are 
the investigation of choice for grade 1 and 2 NETs [5, 116].  Higher spatial resolution 
compared to Octreoscan also aids in the detection of smaller lesions.  It is not sensitive for 
poorly differentiated NET cells which may not express SSTR. 
 
1.1.7.3.5 18FDG-PET  
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For grade three poorly-differentiated NETs where  tumours express lower levels of SSTR, 
18-fluorodeoxyglucose (FDG)-PET may add additional value as it has been shown to have a 
sensitivity of 92% [117]. FDG-PET may reveal previously undetected lesions of poorly 
differentiated NET; avidity is associated with poor prognosis (Binderup et al., 2010). 
 
 
1.1.7.4 Blood sampling techniques 
 
Highly specialised techniques for the detection of radiologically-undetectable functioning 
PNETs include transhepatic portal venous sampling (THPVS) and arterial stimulation venous 
sampling (ASVS). These techniques seek to localise pancreatic lesions to a particular 
anatomical region of the pancreas in an effort to plan treatment.  THPVS involves sampling 
of blood from small peripancreatic veins for the measurement of hormone levels, while 
ASVS involves the administration of agents that stimulate hormone secretion such as secretin 
for gastrinomas into the arterial supply of the pancreas and measuring hormone levels of the 
hepatic venous blood [100, 118, 119].  This more recent technique has been shown in one 
study looking at gastrinomas to have a high sensitivity (89%) and fewer complications when 
compared to THPVS [119]. 
 
 
1.1.7.5 Intraoperative localisation 
 
Intraoperative ultrasound coupled with manual palpation of the pancreas have shown 
sensitivities of 83-100% across various studies [100, 120, 121].  These methods can be used to 
aid in the localisation of F-PNETs in cases where preoperative imaging has failed. 
 
 
1.1.7.6 Tissue biopsy 
 
Histological confirmation is also required to establish the diagnosis of PNET [122, 123]. The 
primary lesion is most commonly biopsied by fine-needle aspiration (FNA) during an EUS 
procedure, ideally with a cytopathologist present to reduce the occurrence of unsatisfactory 
samples for diagnosis. Less common techniques include brush cytology and endoscopic 
trans-papillary biopsy during Endoscopic Retrograde Cholangiopancreatography (ERCP). 
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Liver metastases, which account for the majority of PNET metastases are usually biopsied 
percutaneously (by FNA) under image-guidance (either using US or CT) [123] Pathological 
features confirming PNET are discussed in section 1.1.8 below. 
 
 
1.1.8 PATHOLOGICAL FEATURES OF PNETS 
 
In light of the heterogeneity of PNETs and various staging systems, the College of American 
Pathologists (CAP) released recommendations for the structure of pathology reports [124]. 
Suggested components of the classification system include: 
 
 
1.1.8.1 Tumour location 
 
Anatomical subdivision of the pancreas allows for classification of lesion by location.  
Divisions include [124]: 
•   Head of pancreas: To the right of the left border of the superior mesenteric vein 
(SMV).  Includes uncinate process 
•   Body: Between left border of superior mesenteric vein and left border of aorta 
•   Tail: between left border of aorta and splenic hilum  
 
 
1.1.8.2 Tumour dimensions 
 
Lesions <5 mm in size are considered ‘microadenomas’ and are seen in greater amounts in 
patients with syndromic PNETs [53].  Tumours greater than three centimetres in size have 
been associated with features of aggressive behavior, including local and vascular invasion as 
well as metastasis, although it must be noted that size varies greatly in both localised and 
metastatic tumours [21, 125].  
 
 
1.1.8.3 Tumour focality 
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Multifocality is common in MEN1 cases as well and has been described in up to 30% of 
gastrinomas and 13% of insulinomas.  It is recommended that resected specimens are 
examined in three to five millimetre sections to enable adequate detection of microadenomas 
within the pancreatic tissue [124]. 
 
 
1.1.8.4 Macroscopic features 
 
PNETs are usually solid, brown-to-red homogenous lesions very occasionally encased in a 
fibrous pseudocapsule.  Unlike adenocarcinomas which infiltrate as they grow, PNETs 
exhibit an expansive pattern of growth, compressing and distorting surrounding structures. 
They are usually highly vascular and in larger lesions, zones of necrosis may be evident. 
Perivisceral fat involvement, invasion of the duodenal wall, common bile duct, spleen or 
large vessels are features suggestive of malignancy [126]. 
 
 
1.1.8.5 Microscopic Features 
 
Discohesive, clustered cells containing round and eccentric nuclei with a ‘salt and pepper’  
chromatin pattern and fine, granular cytoplasm are all cytological features of PNETs [123]. In 
most cases, nucleoli are absent or difficult to identify, although very occasionally they are 
prominent [126]. 
 
 
1.1.8.6 Immunohistochemistry 
 
Examination of tumours using haematoxylin-eosin stained sections allows for the diagnosis 
of a PNET in most cases, however immunohistochemical confirmation of at least one general 
endocrine marker; chromogranin A or synaptophysin is necessary [126-128]. Other markers 
such as cytokeratins can aid in making the diagnosis, while hormones produced by tumours 
(such as insulin, glucagon, SS, PP, gastrin, VIP and adrenocorticotrophic hormone) can also 
be shown through labelling [126].  More recently, immunohistochemical markers as 
predictors of prognosis has been an area of interest with several potential candidates such as 
COX2, p27 and CD99 being proposed [129-131]. 
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1.1.8.7 Functional type 
 
As previously discussed, tumours are either functioning or non-functioning. Non-functioning 
hormones may produce hormones but clinical symptoms do not result. This is thought to be 
due to either in inactive forms of hormones being produced, inadequate amounts or impaired 
pathways for secretion meaning that these products are not released into the circulation [126].  
Consequently, immunohistochemical staining for such peptides is not in itself of great value; 
findings must be correlated with a patient’s preoperative symptoms. 
 
 
1.1.8.8 Differentiation  
 
Well-differentiated cells appear small, round and monomorphic, while cellular pleomorphism 
is a feature of poorly-differentiated lesions [11, 19]. 
 
 
1.1.8.9 Mitotic activity 
 
Two measures are used to indicate the proliferative rate of PNETs; mitoses per high power 
field (HPF) and Ki67 index. Mitoses per 10 or per 50 HPF provides an indication of the 
replicative potential/behavior of tumour cells.  It is measured in 50 HPF in the area of highest 
mitotic activity and is reported as mitoses per 10 HPF. High mitotic activity has been 
correlated with malignant potential [125], however, a low mitotic index does not necessarily 
mean the converse; in many instances malignant tumours have exhibited little or no mitotic 
activity [132]. The nuclear protein ki67 serves as an indicator of cellular proliferation.  It is 
present within the cell nucleus during interphase, relocating to the surface of chromosomes 
during mitosis.  Its presence during all active phases of the cell cycle (G1, S and G2) and 
absence in resting cells (G0) make it a reliable indicator of a cell population’s growth fraction 
[133]. 
 
 
1.1.8.10 Tumour necrosis 
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When present, non-ischaemic tumour necrosis is usually seen in poorly-differentiated PNETs 
and is commonly thought of as being a feature associated with malignancy [124]. 
 
 
1.1.8.11 Margins 
 
Complete resection of a lesion is a strong determinant of long-term patient survival [134, 
135].  Sections through the closest extent of the tumour to the pancreatic resection margin 
and retroperitoneal/uncinate process margin are recommended. Examination of the deep 
radial surface (essentially the posterior retroperitoneal surface of the specimen) is also 
suggested [124]. 
 
 
1.1.8.12 Vascular and Perineural invasion 
 
Invasion into blood vessels (especially tumour capsule veins) and perineural spaces have 
reportedly been seen in up to 90% of cases associated with distant metastases [136]. In other 
series, the presence of perineural invasion has been correlated with malignant (metastasis) 
and decreased patient survival [137]. 
 
 
1.1.8.13 Lymph node involvement 
 
Regional lymph nodes (LN) are classified into several groups based upon anatomical 
location.  These are as follows: 
•   Superior = LN superior to head and body of pancreas 
•   Inferior = LN inferior to head and body of pancreas 
•   Anterior = Anterior pancreaticoduodenal, pyloric and proximal mesenteric LN 
•   Posterior = Posterior pancreaticoduodenal, common bile duct or pericholedochal and 
proximal mesenteric LN 
•   Splenic = Splenic hilum and pancreatic tail LN (only in body and tail tumours) 
 
Also considered regional lymph nodes are: 
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•   Infrapyloric, subpyloric and coeliac nodes (for tumours of the pancreatic head only) 
•   Pancreatico-lieno and splenic nodes (for tumours in the body and tail only) 
•   Hepatic artery, retroperitoneal and lateral aortic nodes 
 
Involvement of lymph nodes other than these are classified as distant metastases [124]. 
 
There is no consensus on the number of lymph nodes required for satisfactory staging of 
PNETs resected by pancreaticoduodenectomy, a minimum of 12 has been suggested for 
adenocarcinoma of the pancreas [124]. 
 
 
1.1.9 GRADING AND STAGING  
 
The rarity and heterogeneity of PNETs has posed a considerable challenge to the 
development of a classification system that is able to predict the clinical behaviour and 
prognosis of any given tumour, as well as developing best practice management guidelines.  
In recent years the World Health Organisation (WHO), American Joint Committee on Cancer 
(AJCC), North American Neuroendocrine Tumour Society (NANETS) and European 
Neuroendocrine Tumour Society (ENETS) have all developed classification systems 
applicable to all NETs, not just those of the pancreas.  Limitations common to all systems are 
that they do not differentiate between NF-PNETs and F-PNETs and do not separate sporadic 
and syndrome-associated PNETs. In general, PNETs are referred to according to their 
grading as defined by the WHO system as well as their Tumour, Nodes, Metastases (TNM) 
stage. 
 
 
1.1 9.1 European Neuroendocrine Tumour Society (ENETS) staging system  
 
The European Neuroendocrine Tumour Society (ENETS) released proposed for standardised 
diagnostic and staging approach for neuroendocrine tumours in 2006 and 2009. This system 
was the first specifically targeted at PNETS, accounting for their more indolent behaviour 
compared to adenocarcinomas and its prognostic value was substantiated by several studies 
[19, 132]. 
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Table 2 : ENETS staging system for PNETS [132, 138] 
 
 
1.1.9.2 World Health Organisation (WHO) 2010 grading system 
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In 2010, the World Health Organisation WHO classification system was released.  This 
system essentially endorsed the ENETS system, stratifying patients into low, intermediate 
and poorly differentiated categories (Grade 1, 2 and 3 respectively) based on histological 
differentiation. The main point of contention with this system has, however, been the 
heterogeneity of grade 3 tumours; that is, some tumours with a high ki67 index are classified 
as grade 3 tumours despite being well-differentiated.  However, their clinical behaviour is 
less aggressive than tumours classified as grade 3 based on poor differentiation.  
 
 
 
Table 3: ENETS/WHO classification system for neuroendocrine tumours [138] 
 
 
1.1.9.3 American Joint Council for Cancer (AJCC)/Union for International Cancer 
Control (UICC) System  
 
For PNETS, this system essentially uses the Tumour Nodes Metastasis (TNM) criteria used 
for pancreatic adenocarcinoma and is currently in its seventh edition (2010). 
 
	   31	  
 
 
 
Table 4: AJCC/UICC classification system for neuroendocrine tumours (seventh 
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edition)  [138] 
 
 
T stage ENETS system AJCC/UICC system 
T1 
 
Confined to pancreas, <2cm Confined to pancreas, <2cm 
T2 Confined to pancreas, 2-4cm Confined to pancreas, >2cm 
T3 Confined to pancreas, >4cm or 
invasion into duodenum or bile duct 
Peripancreatic spread, but absence major 
vessel involvement  
T4 Invasion of adjacent organs or major 
vessels 
Major vessel involvement 
 
Table 5: Comparison between tumour stages in ENETS and AJCC/UICC systems 
 
 
1.1.9.5 Choice of staging system 
 
Retrospective evaluation of data has proven the prognostic ability of both the AJCC/UICC 
and ENETS systems [139] and both systems have been shown to have prognostic value for  
for relapse-free and overall survival [132, 140]. In their 2012 publication, Strosberg et al 
compared both the AJCC/UICC and ENETs systems in 94 patients with non-metastatic, 
resected PNETs.  They reported recurrence-free survival (RFS) rates for stages I, II and III 
disease as being 90%, 73% and 66% respectively, using the AJCC/UICC staging system.  
Using the ENETs system, RFS rates were 100%, 84% and 75% respectively [141].  The same 
institution published another analysis in 2011 looking at overall survival (OS) in a series of 
425 patients treated over a period of 11 years.  OS rates for stage I, II, III and IV were 92%, 
84%, 81% and 577% using the AJCC system vs 100%, 88%, 85% and 57% respectively 
using the ENETs system [142].  
 
Improvements in staging systems are a continuous focus of research; the eighth edition of the 
AJCC/UICC TNM staging system is now available due to come into effect in the United 
States from January 1, 2018 and will make a distinction between PNETs and pancreatic 
exocrine tumours [78]. Essentially, it is a combination of the AJCC/UICC and ENETS 
systems, using ENETS definition of T stage as well as prognostic stage groupings (Table 6). 
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Table 6: AJCC/UICC classification system (8th Edition) [138] 
 
 
 1.1.10 MANAGEMENT 
 
As PNETs are such a diverse group of cancers in terms of both presentation and biological 
behaviour, careful assessment and evaluation by a multidisciplinary team is necessary to 
determine the most appropriate course of treatment for patients. Emerging research has 
focused on the development of personalised therapies, based upon individual tumour 
characteristics.  Recent publications have also presented advances in locoregional and 
systemic treatments (particularly for liver metastases) as well as investigating the efficacy of 
various combinations of these [143]. The main principle of treatment includes complete 
resection for localised lesions.  For metastatic disease, or in cases of recurrence, surgery may 
be combined with locoregional and/or systemic treatment modalities [144] to control local 
and systemic symptoms and prevent malignant transformation or metastasis. 
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1.1.10.1 Surgery 
 
Complete surgical resection is the only potentially curative option for the treatment of 
PNETs.  Unfortunately, a large proportion of patients with PNETs, particularly NF-PNETS, 
present with advanced disease not amenable to curative resection [145].  Improvements in 
long-term survival can, however, still be achieved in many patients [146]; if curative 
resection of the primary tumour and associated lymph nodes is not attainable, there may be a 
role for debulking surgery. Tumour size, grade and extent of disease are the main 
determinants of surgical management.  In every instance, careful evaluation of the potential 
morbidity associated with any operative procedure against the likely biological behaviour of 
the tumour is critical. 
 
 
1.1.10.1.1 Distinction between resectable and unresectable disease 
 
Disease restricted to the pancreas without involvement of surrounding structures is 
considered resectable; this includes stage IA, IB and IIA tumours. Lesions with borderline 
resectability include those where the tumour may have approached nearby structures such as 
blood vessels but is still likely to be amenable to an R0 resection (some stage III lesions).  
Unresectable lesions include those that are locally-advanced (infiltrating surrounding blood 
vessels as is the case with stage IIB and most stage III lesions) and those that have 
metastasised (stage IV lesions). 
 
 
1.1.10.1.2 Extent of resection 
 
Curative resection requires removal of the primary tumour and involved lymph nodes whilst 
preserving as much pancreatic tissue as possible [147]. For lesions involving the head, 
uncinate process or neck of the pancreas, pancreaticoduodenectomy is usually performed.  
Very occasionally, enucleation may be a viable option. Lesions of the body or tail are usually 
resected by distal pancreatectomy with associated splenectomy if malignant tumour behavior 
is suspected.  Central pancreatectomy and in rare cases enucleation may be possible in these 
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types of tumours.  Finally, in instances of multifocal disease, a total pancreatectomy may be 
necessary to resect the disease in its entirety [138]. 
  
 
1.1.10.1.3 Surgery in NF-PNETS 
 
For smaller lesions, current recommendations from the National Comprehensive Cancer 
Network suggest observation of PNETS less than one centimetre in size can be considered 
instances where malignant features are absent [26]. Larger lesions should be resected, and in 
the presence of malignant features, patients should be subject to complete oncological 
resection with the aim of attaining an R0 resection. Resection is advised whenever possible, 
even in the presence of unresectable metastatic disease, as it has been shown to confer a 
survival advantage [148-152]. 
 
 
1.1.10.1.4 Surgery in F-PNETS 
 
For insulinomas and gastrinomas less than two centimetres in size that do not abut the main 
pancreatic duct, or in patients who are poor operative candidates, enucleation may be 
performed as, in most cases, these tumours are benign [148, 149, 152, 153]. In VIP-omas, of 
which up to 60% are metastatic by the time of diagnosis, the liver and lymph nodes must be 
carefully assessed before and during surgery; there may be a role for debulking of liver 
metastases to aid in symptom control [132]. Assessment of the liver and possible debulking 
of metastases are also recommended for glucagonomas and somatostatinomas [78]. 
 
 
1.1.10.1.5 Role of Surgery in Metastatic Disease 
 
1.1.10.1.5.1 Liver dominant metastatic disease 
 
Many NF-PNETS present as locally-advanced tumours, with liver metastases in 60-80% of 
cases [3, 45].  Data from older series predominantly involving gastrinomas suggested that 
resection in cases of isolated low volume hepatic metastases (<50% liver involvement) may 
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confer a survival benefit, provided that >90% of tumour burden is resected. Surgery can 
result in symptom reduction, improved oncologic outcomes and long-term survival [154].  
  
 
1.1.10.1.5.2 Widespread metastatic disease 
 
Systemic medical therapy forms the mainstay of treatment in unresectable metastatic disease. 
Debulking surgery can aid in symptom palliation and management of complications such as 
gastric and biliary obstruction [92, 144]. Several factors must be considered in this instance, 
including the histological features or the tumour, burden and rate of disease spread [78]. As 
NF-PNETs do not produce symptoms of hormone excess, in some instances (depending on 
tumour location), resection of the primary lesion in the cases of widespread metastases in the 
absence of complications resulting from tumour mass effect is not warranted [78]. 
 
 
1.1.10.1.5.3 Liver transplant 
 
The utility of orthotopic liver transplant in PNETS is not well established. Recent data 
suggest although it is feasible for some of these patients to under go liver transplant, a 
significant number of these patients will relapse [155]. Currently, In Australia, the majority 
of these patients would not be considered candidates for surgery. Additionally, it’s 
application is restricted to metastases confined to the liver, and even in this instance, the 
tumour recurrence rate is high [110, 156].  
 
1.1.10.1.6 Surgery in recurrent disease 
 
In cases of recurrence, debulking has been shown to provide some improvement in long term 
survival and symptom palliation in selected patients, although extensive data on this is not 
available [71]. In the presence of unresectable hepatic disease, guidelines from ENETS and 
National Comprehensive Cancer Network (NCCN) advocate the use of regional liver-
directed therapies, however, resection of the primary lesion has been advocated in some 
instances [138]. 
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1.1.10.1.7 Lymphadenectomy 
 
Despite our evolving knowledge on the optimal management for PNETS, there is still 
insufficient evidence to guide degree of lymphadenectomy required and potential for splenic 
preservation in distal pancreatectomy in surgical resection [21, 157-159]  
 
 
1.1.10.1.8 Surgical management of familial PNETS  
 
In patients with MEN1 who develop gastrinomas, there is no clear consensus on when 
medical therapy versus surgical treatment should be utilised, particularly as surgery for 
primary gastrinoma is unlikely to be curative [160] (its main benefit being decreasing 
mortality from metastatic gastrinoma) [50]. Treatment of hepatic metastases can be through 
surgical debulking, hepatic artery chemoembolisation or systemic chemotherapy; once again, 
no clear evidence exists as to which is best [50]. 
 
For MEN1 patients with insulinomas, local excision of pancreatic head tumours along with 
distal pancreatectomy is sometimes advocated.  This due to the fact that multiple, small 
lesions are often present that may be missed through pre- and intraoperative localisation 
methods. In patients that develop NF-PNETs, if non-metastatic, then tumour size usually 
dictates when operative intervention should occur, although there is little evidence supporting 
this method [161]. Some publications have reported no survival benefit from resecting such 
lesions, suggesting that these tumours should undergo surveillance unless rapidly-enlarging 
or symptomatic [55, 68, 162-165].   
 
Careful consideration before surgery has also been advocated in PNETs associated with 
VHL.  These cases tend to be unifocal and are often not the cause of death in these patients 
[166].  In a large prospective series conducted at the National Cancer Institute, 108 patients 
with von Hippel-Lindau disease and NF-PNETS underwent either surgical resection or 
surveillance with serial imaging depending on tumour size. Blansfield et al concluded that 
NF-PNETs smaller than three centimetres in size without a mutation in exon 3 and with slow 
doubling time (< 500 days) can be safely monitored by radiological surveillance alone [167, 
168]. 
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1.1.10.2 Locoregional therapies 
 
A range of locoregional therapeutic options are currently available for the treatment of 
hepatic metastases not amenable to surgical resection.  These include bland arterial 
embolisation, transarterial chemoembolisation (TACE), selective internal radiation therapy 
(SIRT) and radiofrequency ablation (RFA). These liver-directed therapies can be used in 
combination with other therapies when the symptom burden is dominated by hepatic 
metastases and are discussed below. 
 
 
1.1.10.2.1 Bland embolisation and transarterial chemoembolisation  
 
75-80% of PNET liver metastases derive their blood supply from the hepatic artery (unlike 
normal liver parenchyma, which derives its supply from the portal vein) [169, 170]. 
Transarterial embolisation utilises this property of differential blood supply, so metastatic 
deposits in the liver are preferentially targeted via hepatic arteries whilst surrounding normal 
liver parenchyma is preserved as portal venous supply remains unaffected [92, 144].  This 
treatment requires a patent portal vein and good functional status. It is used in liver-only 
metastases or in systemic disease with liver-dominant symptoms. 
 
In addition to bland embolisation, transarterial chemoembolisation or TACE, can deliver a 
variety of chemotherapeutic agents, and is commonly utilised in the treatment of hepatic 
deposits of metastatic PNETs not amenable to surgical resection. Systemic and tumour 
volume effects for both bland and chemoembolisation have been seen in studies on 
neuroendocrine tumours at a range of body sites [3, 45]. 
 
 
1.1.10.2.2 Selective internal radiation therapy 
 
Selective internal radiation therapy (SIRT) or radioembolisation, has also been utilised as a 
form of liver-directed therapy.  Radiolabelled microspheres are injected into the tumour 
vasculature, and used to direct local radiation therapy. Kennedy et al reported results of 
microspheres containing yttrium-90 in a series of neuroendocrine tumour liver metastases 
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from various primary sites [171].  Given the availability of several options, a 
recommendation was made in the 2011 Consensus report of the National Cancer Institute 
Neuroendocrine Tumour Clinical Trials Planning Meeting, to perform randomised phase II 
trials comparing bland-, chemo- and radioembolisation and assess efficacy and evaluate risk 
benefit profiles of each method [172]. 
 
 
1.1.10.2.3 Ablation therapies 
 
Ablative interventions including radiofrequency ablation (RFA), alcohol ablation and 
cryotherapy have all been utilised in the treatment of unresectable liver metastases, with RFA 
being the most widely employed technique. In their study on examining the use of RFA in 
neuroendocrine liver metastases, Mazzaglia et al reported complete or significant alleviation 
of symptoms in 70% of patients (18 of whom had PNETs). Five-year survival in these 
patients was 48% [173]. RFA is associated with low morbidity and mortality and can be 
administered either percutaneously or laparoscopically.  It is most effective in the presence of 
fewer than ten lesions, each being smaller than four centimetres in size [143, 144] and can be 
used exclusively or as an adjunct to surgical resection.  Microwave ablation is a newer 
approach which has been studied more extensively for the treatment of hepatocellular cancer, 
but has more recently been found to have a role in the treatment of neuroendocrine liver 
metastases [143, 173]. 
 
 
1.1.10.3 Systemic therapies 
 
Advances in molecular biology over the past decade have led to an expansion of effective 
systemic therapies such as somatostatin analogues (SSAs), targeted therapies such as 
sunitinib and everolimus and peptide receptor radionuclide therapy (PRRT). which have 
revolutionised the treatment, particularly for grade 1 and 2 NF-PNETs.  
 
 
1.1.10.3.1 Somatostatin analogues  
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Somatostatin analogues (SSAs) such as octreotide LAR and lanreotide were originally used 
to treat symptoms of carcinoid syndrome, but their antiproliferative properties (through their 
action on somatostatin receptors) have been demonstrated in two recent randomised trials. 
Consequently, recommendations for their use as first-line therapy in advanced low-grade NF-
PNETs  have been made.[89, 174, 175]. The PROMID study [176] showed that octreotide 
LAR, compared to placebo, showed improved time to tumour progression in 85 patients with 
grade 1 midgut NETs. The CLARINET trial [177] similarly showed that lanreotide improved 
progression-free survival (PFS) (median not reached vs. 18.0 months, hazard ratio (HR) 0.47, 
P<0.001) compared to placebo in 204 patients with grade 1-2 (Ki67<10%) gastrointestinal 
NETs (91/204 of which were pancreatic). The PFS HR was not significant in the pancreatic 
subgroup, but was numerically comparable (0.58) to the overall effect. Pasireotide LAR is 
another SSA undergoing investigation. A randomised phase III trial (n=110) showed no 
difference between pasireotide and octreotide in symptom control, although PFS was 
improved in a post-hoc analysis [178].  
 
 
1.1.10.3.2 Peptide receptor radionuclide therapy (PRRT)  
 
This form of molecular therapy utilises the high expression of somatostatin receptors in 
PNET cells. An active agent (usually Yttrium-90 or Lutetium-177) with a high affinity for the 
SSTR is attached via a chelating agent (DOTATATE or DOTATOC) to an active 
radionuclide. This results in delivery of radioactivity to neuroendocrine tumour cells 
expressing the SSTR-receptor. The course of treatment usually involves four intravenous 
injections six to ten weeks apart. Avidity of lesions on 68Gallium PET or Octreoscan is 
required for effective treatment. The first randomised trial of PRRT, NETTER-1, involved 
patients with midgut NETs progressing on standard dose SSA being randomised to increased 
dose of SSA or PRRT with 177Lu-DOTATATE. Patients in the latter group demonstrated 
significant improvements in PFS at month 20 (65.2% [95% CI, 50.0-76.8] compared to 
10.8% [95% CI, 3.5-23.0] in the control group [179].  
 
 
1.1.10.3.3 Chemotherapy 
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Over the past few decades, chemotherapy was used widely in treatment of advanced PNETs, 
but more recently this practice has become less frequent, as other efficacious, less toxic 
systemic treatment options have been developed. Agents such as streptozocin, fluorouracil, 
and doxorubicin [180] [181] [182] have all demonstrated modest response rates. In addition, 
CAPTEM, the combination of capecitabine and temozolomide, has demonstrated an 
impressive 43% response rate for NFPNETs [183] with ongoing trials in progress 
(NCT01824875). Cisplatin and etoposide was shown to be efficacious in poorly-
differentiated PNETs but less so in well-differentiated NETs [184]. It is one of the first-line 
options for grade 3 PNETs, with carboplatin often used instead of cisplatin due to its 
favourable side effect profile. For potentially indolent tumours, streptozocin-based 
combination chemotherapy is currently recommended only in patients with symptomatic or 
progressive advanced grade 1-2 PNETs, with platinum/etoposide chemotherapy for patients 
with grade 3 PNETs. [89, 185].  
 
 
1.1.10.3.4 Vascular endothelial growth factor pathway inhibitors 
 
Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) pathway 
have been a promising therapeutic option due to the highly vascular nature of  
PNETS. One such agent sunitinib, is an oral tyrosine kinase inhibitor targeting VEGF 
receptor 1/2/3, platelet-derived growth factor receptor (PDGF) and c-kit. A phase III trial in 
patients with advanced grade 1-2 PNETs [186] showed that sunitinib 37.5mg daily compared 
to placebo improved progression-free survival (11.4 vs 5.5 months; HR 0.42; P<0.001), 
response rate and overall survival (HR 0.41; P=0.02). Common side effects included 
diarrhoea, nausea, asthenia, hypertension and fatigue. Pazopanib, another multi-targeted 
tyrosine kinase inhibitor of angiogenesis, PDGF and c-kit, showed a response rate of 22-25% 
in two phase II trials of patients with metastatic NETs (Phan Lancet Oncol 2015) [187]. A 
current study investigating its combination with temozolomide is in progress 
(NCT01465659).  
 
 
1.1.10.3.5 Mammalian target of rapamycin inhibitors 
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Mammalian target of rapamycin (mTOR) is a serine-threonine protein kinase involved in cell 
cycle regulation, cell growth, proliferation, metabolism and apoptosis [188]. At the cellular 
level, many PNETs demonstrate dysregulation of the mTOR pathway, thereby rendering it a 
therapeutic target for agents such as everolimus [189]. The role of everolimus in treatment of 
advanced PNETs was investigated in the RADIANT-3 trial [190]. Everolimus significantly 
prolonged PFS compared to placebo (11 vs 4.6 months; HR 0.35; P<0.001), although the 
objective response rate was only 5%. Side effects included stomatitis, rash, diarrhea, 
hyperglycaemia and pneumonitis. The choice of systemic agent may be driven by patient 
factors and drug toxicity profile (for example, preference for sunitinib over everolimus in a 
patient with diabetes mellitus, and vice versa in the case of uncontrolled hypertension) [191]. 
 
 
1.1.10.3.6 Immunotherapy 
 
Interferon alpha is an immune-modulating agent used in metastatic PNETs for its anti-
proliferative, apoptotic and cytostatic effects. The addition of interferon alpha to SSAs has 
been shown to improve carcinoid symptoms but not survival in randomised trials [192]. 
Frequent toxicities such as ‘flu-like’ symptoms, depression and various blood dyscrasias have 
limited its widespread use [92, 193].  
 
 
1.1.11 MONITORING AND SURVEILLANCE 
 
There is no clear consensus on the frequency or duration for surveillance of patients with 
PNETs, partly due to the variation in clinical course. Patients with resected PNETs should be 
monitored with serum biomarkers (such as periodic CgA levels), and structural and 
functional imaging (such as contrast CT or 68Gallium-DOTATATE-PET). In metastatic 
disease, follow-up should be tailored to the tumour grade, patient condition and treatment 
administered. For patients with MEN1 and VHL whose disease is restricted to the pancreas, 
EUS may be a more appropriate surveillance technique, given its higher sensitivity at 
detecting smaller, intra-pancreatic tumours [92]. 
 
 
1.1.12 PROGNOSIS 
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Prognosis is largely dependent upon clinical stage of the tumour as classified by the WHO 
and various TNM staging systems [18], which depend on size of the primary tumour, nodal 
involvement, the presence of metastases as well as tumour histology [92]. [143]. Location of 
primary tumour, patient age and time since diagnosis are also predictors of prognosis [8].  
 
Figures published in the SEER database suggested that up to 64% of patients with NF-PNETs 
present with distant metastases and that the five-year survival rate in this group of patients is 
27% [4].  Patients with NF-PNETs are more likely with metastatic, unresectable disease 
given the absence of an associated clinical syndrome. For NF-PNETs overall, five-year 
survival rates ranging from approximately 40-70% have been reported; this variance can be 
attributed to the heterogeneity of patients in studies, which includes poorly- and well-
differentiated tumours with both locally advanced and metastatic disease [72, 146, 149, 194-
196].  Other studies have echoed this suggestion that the presence of metastatic disease is a 
crucial predictor of survival [197]. Of the F-PNET subtypes, most glucagonomas, VIPomas 
and somatostatinomas present with associated metastases at the time of diagnosis [4], 
compared with less than 50% of gastrinomas and less than 15% of insulinomas. PNETs that 
occur in the context of an inherited genetic syndrome tend to exhibit a more indolent course 
than sporadic PNETs and therefore are associated with a better prognosis [19]. 
 
 
1.1.13 SUMMARY  
 
Over recent years, our awareness and understanding of PNETs has increased substantially, 
however the relative rarity and heterogeneity of these tumours continues to be a significant 
hindrance to providing the satisfactory study populations required to develop and advance 
treatment strategies. The increased use of cross-sectional imaging has seen a rise in the 
number of cases and earlier detection of PNETs, thereby providing an opportunity for earlier 
intervention and improved outcomes. Evaluation of the primary tumour and, if present, 
metastases has also benefitted from the continued improvements in resolution of cross-
sectional imaging and the development of nuclear medicine imaging techniques. 
 
However, the existence of several different classifications systems has highlighted the 
deficiency in our understanding and lack of consensus on the prognostic indicators for 
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PNETs.  Further work is needed to elucidate the importance of different prognostic factors 
and identify more reliable biomarkers for PNETs. To date, most studies have looked at all 
types of PNETs together, regardless of their functional status or histopathological 
characteristics, so it has been difficult to gain a detailed understanding and ascertain the 
effectiveness of the various treatments on the different PNET subtypes.  The Neuroendocrine 
Tumour Taskforce of the National Cancer Institute Gastrointestinal Steering Committee has 
identified this issue, and as a result made several recommendations to guide future research.  
Amongst these is the recommendation that PNETs be stratified into well- and poorly-
differentiated histologies for the purpose of research. 
 
For disease not amenable to surgical resection, we now have a myriad of non-surgical 
treatment options with varying mechanisms of action to utilise.  Despite this, curative options 
for advanced disease have not been discovered, with only improvements progression free 
survival being achieved.  Several studies looking at combinations of non-surgical therapies 
are underway, in an effort to improve current practice. Further elucidation of the molecular 
pathogenesis of PNETs will help not only improve existing treatments, but may also unveil 
prognostic biomarkers and targets for novel therapeutics, thereby paving the way for the 
development of potentially curative treatments in the future.  Studies involving the genetic 
profiling of individual PNETs and correlation with responses to individual therapies and 
prognosis will also aid in the development and validation of treatment algorithms that will 
enable the provision of optimal individualised treatment for patients affected by this 
heterogeneous disease.  
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1.2 MICRORNAS IN PNETS 
 
1.2.1 INTRODUCTION 
 
MicroRNAs are small, endogenous non-coding RNAs. Single-stranded and approximately 22 
nucleotides in length, they are thought to regulate gene expression during the post-
transcriptional phase [198].  It is estimated that microRNAs regulate around 30% of the 
protein-coding genome in humans. Discovery of the the first microRNA, Lin-4 in the 
nematode C. elegans took place in 1993 [199, 200] by Lee and colleagues, who discovered 
that Lin-4 regulated the Lin-14 mRNA when going between larval stage one and two in the 
lifecycle [199].  Prior to this, the widely accepted central dogma that DNA was transcribed 
into RNA and then translated into proteins meant that non-protein coding sequences were not 
a focus of research [200]. Over the next decade, many different miRNAs were discovered 
and found to be differentially expressed in different cell types of of a wide range of 
organisms, raising the possibility that, perhaps, these various miRNAs played different roles 
in regulating the expression of a variety of genes. 
 
 
1.2.1.1 Biogenesis of MicroRNAs and their mechanisms of action  
 
The canonical pathway for microRNA formation begins with formation of a much larger 
primary transcripts or pri-microRNAs and are usually transcribed by RNA polymerase 2.  
The pri-microRNA folds into a stem-loop structure (some unpaired nucleotides are usually 
found at the 3’ and 5’ ends).  In some cases, just one hairpin structure is made from the initial 
gene, in other cases three hairpins are made from the one gene to yield three different 
microRNAs. Occasionally, the primary transcript for the microRNA is multifunctional, 
containing a pre-messenger RNA which is spliced to give a mature mRNA (that is then 
translated into protein), while the intron codes for a hairpin segment. 
 
This structure is then recognised by and acts as the substrate for the endonuclease/enzyme 
Drosha (a nuclear RNase 3 enzyme) and its partner DGCR8/PASHA, a specialised RNA 
binding protein.  Together, they form the microprocessor complex.  This complex performs a 
cleavage reaction that removes the 5’ and 3’ extensions (at a point about one helical turn 
from the base of the hairpin to yield a 60-70 nucleotide hairpin structure, termed a ‘pre-
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microRNA’. 
 
The pre-microRNA is then recognised by nuclear transporter the Exportin 5 complex, which 
transports the pre-microRNA from the nucleus to cytoplasm for further processing. 
 
In the cytoplasm, a second endonucleatic cleavage reaction, referred to as ‘dicing’ occurs. 
This is catalysed by ‘dicer’, an RNAse 3 enzyme.  Dicer exists in a complex with TRBP2, a 
binding protein and PACT.  This second cleavage reaction removes the ‘loop’ of the hairpin 
and yields a miR:miR* duplex (~22 nucleotides in length) which carries 5’ monophosphates 
and 3’ overhangs of two nucleotides that are not fully complementary. 
 
The two strands of the structure are known as the ‘guide strand’ and ‘passenger strand’, the 
guide strand usually being the one which has the least stable pairing at the 5’ end (rendering 
it less thermodynamically stable).  Very rarely, both strands will exhibit an equal propensity 
to enter the silencing complex and regulate genes, however in the majority of cases there is 
just one that does so.  The complex now meets the argonaute protein (AGO), that is dedicated 
to miRNA silencing reactions.  If correctly loaded, the MiR guide strand is retained and 
loaded onto the AGO protein, while the miR* strand is selectively removed (a process known 
as ‘sorting’).  The guide strand determines which target RNAs will be silenced, and the 
complex it forms with the argonaute protein (AGO) is known as the miRISC complex or 
silencing complex.  The passenger strand is degraded via an unknown mechanism. 
 
The complex is then ready to bind its target RNA and promote gene silencing and the 
argonaute complex is directed towards target messenger RNAs by the microRNA. RISC then 
binds with target mRNAs through base pairing interactions with complementary sites, mainly 
in the 3’UTR of the target mRNAs (occasionally occurs in the coding regions or 5’UTR).   
Argonautes bound to miRNA typically identify sequences with imperfect complementarity in 
the 3’ UTR region of mRNAs. 
 
Although this is the main method for miRNA biogenesis, it should be noted that minor 
pathways that bypass the need for either Drosha [201] or Dicer [202, 203] have been 
described.  
 
The most important pairing region for the microRNA is the ‘seed sequence’, which usually 
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accompanies nucleotide positions two and seven of the microRNA.  The absence of extended 
duplex formation allows the 3’ end of the microRNA to remain tightly bound to the PAZ 
domain of the AGO protein.  This usually renders the PIWI domain of the AGO protein 
unable to bind to microRNAs; so once bound to targets, the miRISC complex recruits 
additional factors including TRNC6, one that includes multiple glycine and tryptophan 
repeats.  This protein is thought to be involved in repressing translation and destabilising the 
mRNA through mechanisms that have not been fully elucidated. 
 
 
1.2.1.2 Mechanism by which microRNA inhibit gene expression 
 
It is thought that miRNAs cause mRNA destabilisation through deadenylation.  The seed of 
the microRNA brings the silencing complex to the 3’ UTR of the messenger RNA.  The 
silencing complex then recruits an adaptor protein which interacts directly with poly-A 
binding protein PABP that interacts with the poly-A tail of the mRNA, whilst at the same 
time recruiting the deadenylase complex (most important is the CCR0 complex) that shortens 
the poly-A tail to a point where it is then de-capped and degraded from the 5’ end.  
Essentially, the microRNA is destabilising the mRNA through the same processes that 
mRNAs normally undergo, but at an accelerated rate by recruiting the adenylase complex.  
The deadenylase complex has a further role (not as significant), which includes suppressing 
the amount of protein made by the mRNAs by inhibiting translation initiation.  However, 
mRNA destablisation/degradation is thought to account for 70-90% of the effect of 
microRNA.  This is contrary to the initial belief that microRNAs simply decreased the 
amount of protein produced by the mRNA, which was the initial hypothesis; we now know 
that the majority of the effect occurs via reduction in the amount of mRNA itself through the 
action of the deadenylate complex [204, 205]. The repressive activity of miRNAs is limited 
by the fact that miRNAs are induced and degraded over time [206]. 
 
 
1.2.1.3 Regulation of microRNA biogenesis 
 
This occurs through several mechanisms, including: 
1. Transcriptional activation or repression 
2. Post-transcriptional modifications  
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3. Processing 
4. Degradation/decay (can be regulated by proteins eg. Xrn2 and cell divisions that ‘phase 
out’ the miRNAs if production rate is lower than rate of degradation) [206]. 
 
Individual microRNAs target multiple mRNAs, exerting their inhibitory effects to differing 
degrees (the way in which this occurs has not yet been elucidated).  It does, however, make 
understanding a microRNA’s effect on gene expression at a global level significantly difficult 
[206]. 
 
Furthermore, gene regulation by miRNAs at the post-transcriptional stage is further regulated 
by RNA binding proteins (RBPs), many of which help play a role in miRNA stability.  It is 
thought that miRNAs and RBPs compete for binding sites on mRNA; hence RBP binding 
would result in reduction of repression by miRNAs.  RBPs can also induce a change in the 
mRNA structure, hindering miRNA binding as is the case with insulin-like growth factor 2 
binding protein 1 (IGF2BP1), which results in mRNAs BTRC and MITF not being able to 
bind miRNAs 183 and 340 respectively [207]. 
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Figure 1: Canonical microRNA biogenesis pathway and general mechanisms of miRNA 
dysregulation in cancer [208] 
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1.2.1.2 MiRNAs in human disease  
 
Since the discovery that miRNAs were prevalent throughout the human genome, the search 
began to identify patterns or ‘signatures’ of miRNA dysregulation in a wide spectrum of 
human diseases. They have since been implicated in a wide range of pathologies, from 
neurodegenerative diseases [209, 210], to obesity [211], to inherited diseases such as 
progressive hearing loss [212] and skeletal/growth abnormalities [213]. 
 
 
1.2.1.3 MiRNAs in human cancer  
 
The first published association between microRNAs and cancer was published in 2002 by 
Eiring et al, who reported that deletion of MiR-15 and MiR-16 (normally located at 
chromosome 13q14) was frequent in patients who developed chronic lymphocytic leukaemia 
(CLL) [214].  Building on this, Calin et al reported that MiR-15 and MiR-16 were deleted or 
downregulated in over 60% of B-cell CLL and proposed that these microRNAs had a role in 
tumour suppression in CLL [215].  Further to this, they went on to report that many 
microRNAs were located at ‘fragile sites’ or regions altered in cancers and that they therefore 
played a role in the pathogenesis of these cancers [215]. MiRNA downregulation has also 
been reported in lung and breast cancers (miRNA Let-7), MiRNA-34 and 34a loss has been 
shown in pancreatic, colon, breast and liver cancers and has also been reported as being a 
predictor of poorer prognosis in CLL [216, 217]. These miRNAs are thought to inhibit 
carcinogenesis through suppression of the translation of oncogenic mRNAs [218]. 
 
Upregulation of MiRNAs has also been described in several malignancies and is thought to 
be oncogenic in these instances. MiR-21 for example, has been reported as being upregulated 
in breast [219] and colon cancer [220] as well as glioblastomas [221].  It’s thought that miR-
21 exerts an ‘anti-apoptotic’ effect through its inhibition of tumour suppressors programmed 
cell death 4 (PDCD4) and phosphatase and tensin homolog (PTEN) [222]. The MiR-17-92 
cluster has been found to be upregulated in several cancers including lymphomas, breast, 
lung colon and stomach cancers [215, 223].  In essence, tumour development is thought to 
result from the downregulation of ‘tumour suppressive’ miRNAs or the upregulation of 
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‘oncogenic’ miRNAs. 
 
In addition to these studies, an exponential body of research into microRNAs in almost every 
human cancer has ensued from initial discoveries almost two decades ago, aided by the 
increasing availability of miRNA microarrays and next-generation sequencing techniques 
which have allowed us to analyse the entire ‘miRNAome’, whilst laboratory techniques 
including quantitative real-time polymerase chain reaction (qT-PCR), high throughput array-
based Klenow enzyme assay and bead-flow cytometry have allowed miRNA expression 
analysis in various tumour types [200, 224, 225].  Consequently, miRNA expression of most 
human cancers has been analysed and reported [224] and the use of microRNA ‘signatures’ 
to diagnose, classify and serve as prognostic markers has been proposed [225]. 
 
 
1.2.1.3.1 Summary of studies with clinicopathological significance 
 
The table below summarises some of the miRNAs that have been found to be aberrantly 
expressed in human cancers [226]. 
 
 
Table 7: Examples of microRNAs involved in the development of human cancers [227] 
 
 
The role that microRNAs play in cancer is based upon their regulation of many genes 
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involved in the DNA damage response (DDR) mechanism [228]. 
 
 
1.2.1.3.2 Mechanisms of MiRNA dysregulation 
 
As single miRNAs can act on a multitude of mRNAs, aberrant miRNA expression can result 
in significant effects on signaling pathways involved in the development of cancer [208]. 
Deregulation of microRNA expression can occur through a variety of mechanisms. The 
major causes include: 
 
 
1.2.1.3.2.1 Genetic alterations 
 
In addition to structural genetic changes, somatic translocations of target sites for miRNAs 
has been reported [229].  This has resulted in mRNAs escaping regulation by inhibitory 
miRNAs.  Mutations involving the seed sequence portion of miroRNAs can result in their 
inability to identify their targets (and potentially act as tumour suppressors here) or result in 
alteration in their target selection [208]. 
 
 
1.2.1.3.2.2 Epigenetic mechanisms 
 
Similar to protein coding genes, miRNA genes can also be affected by epigenetic changes.  
Weber et al reported in 2007 that a significant proportion of miRNA loci are associated with 
CpG islands, and consequently they are likely subject to regulation by DNA methylation 
[230]. Histone acetylation has also been shown to be deregulated in cancers.  Some studies 
have shown that use of histone deacetylase inhibitors (to decrease levels of acetylated 
histones) resulted in decreased expression of anti-oncogenic miRNAs [231, 232]. 
Finally, the link between miRNAs and epigenetic mechanisms is further evidenced by studies 
that have shown that miRNAs can regulate epigenetic ‘machinery’; Fabbri and colleagues 
showed that miR-29 expression was inhibitory to DNMT3A and DNM3TB and that this 
counteracted aberrant DNA methylation [208, 233]. 
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1.2.1.3.2.3 Transcription factors affecting microRNAs 
 
Numerous transcription factors associated with Pol-II (enzyme responsible for RNA 
transcription, discussed in biogenesis pathway section), and in some cases individual 
transcription factors can either repress or activate many miRNAs. An example of this is the 
oncogenic transcription factor Myc, whose main effect is widespread inhibition miRNA 
expression.  Amongst the miRNAs affect are ones with antiproliferative and pro-apoptotic 
actions such as let-7, miR-15a/16-1 and miR34 [234, 235]. 
 
MiRNA downregulation resulting in loss of their anti-tumor effects can also occur as the 
result of loss of tumour-suppressive transcription factors.  An example of this is the well-
known tumour suppressor gene (TSG) p53.  This critical TSG plays a central role in 
governing the cellular response to DNA damage.  In fact, it has been reported that p53 
mutations exist in up to 50% of cancers, whilst in a large majority of remaining cases its 
function is in some way deregulated [208].  In turn, p53 has transcriptional control over many 
miRNAs.  Some studies have reported that MiR-34a,b and c are most strongly upregulated by 
p53.  Gene targets of the miR-34 family include cylcin D, cyclin E2, Cyclin dependent kinase 
4, cyclin-dependent kinase 6 and Myc; these target genes have widespread roles in promotion 
of cell proliferation, cell cycle arrest inhibition and apoptosis, illustrating the link between 
miRNAs and the tumour-suppressor effects of p53 [217, 236-238].  
 
The relationship between miRNAs and these transcription factors is quite complex, however, 
with miRNAs in turn providing negative feedback resulting in an alteration in amount of 
transcription factors [208]. 
 
 
1.2.1.3.2.4 Biogenesis pathway mutation 
 
Defects in the miRNA biogenesis pathway can also result in alterations in miRNA expression 
levels and can result from enzyme and cofactor deregulation.  This is evidenced by studies 
that have looked at key enzymes in the miRNA biogenesis pathway Drosha and Dicer.  These 
enzymes have been shown to exhibit haploinsufficiency; partial deletion of Dicer1 and 
Drosha have been associated with accelerated tumour formation in both in vitro and in vivo 
studies [239].  
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Other factors have also been found to act as haploinsufficient tumour suppressors eg. 
TARBP2 mutations impair miRNA processing, whilst mutations of XPO5 result in miRNAs 
being trapped within the cell nucleus and have been associated with cancers associated with 
microsatellite instability [240, 241].   
 
The previously discussed, TSG p53 can not only govern miRNA expression through its 
action as a transcription factor, but can also influence miRNA expression in a transcription-
independent manner, by interaction with the Drosha complex [242]. 
 
 
1.2.1.3.2.5 Escape from miRNA-induced repression 
 
This can be done in several ways; firstly, through mutations in miRNA target sites in mRNA 
thereby allowing the mRNA to avoid binding and undergoing repression from the miRNA.  
This has been shown to occur in experiments on miRNA let-7, where chromosomal 
rearrangements result in its target gene HMGA2, evading binding and consequently behaving 
as an oncogene [208]. 
 
Another ‘escape’ mechanism includes polyadenylation (also known as alternative splicing), 
which results in the formation of alternative 3’UTRs in mRNAs, thereby changing the 
occurrence of binding/target sites for miRNAs.  Laneve et al described this in their 2007 
publication in which they reported that miR-9 and miR-125a/b act together in neuronal cells 
to regulate proliferation of cells by repressing only the shortened neurotrophin receptor 
tropomysin-related kinase C isoform, not the full length isoform, which does not have a 
binding site for miRNA [243]. In cases of neuroblastoma, miR-9 and miR-125a and b have 
been found to be under-expressed, resulting in abnormal cell proliferation [208]. 
 
Exclusion of target sites on mRNA is another method for evasion of miRNA repression.  
Access to miRNA binding sites can be regulated by secondary structure of the mRNA 
molecule via association with RBPs, thereby regulating miRNA activity.  The RBP known as 
dead end 1 (Dnd1) is an example of this.  This protein binds to uridine-rich regions of some 
miRNAs thereby preventing their binding with miRNAs, as described by Kedde et al in 2007 
[244].  Dnd1 has been shown to prevent binding and repression of miRNA-372 to LATS2, a 
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TSG, raising the possibility that it may play an important role in the development of some 
cancers [244]. 
 
Finally, miRNA activity can be regulated/repressed through the action of mRNA 
‘pseudotargets’ as described by the Competing Endogenous RNA (ceRNA) hypothesis.  This 
theory states that miRNA recognition elements (MREs) on both protein coding and non-
coding transcripts ‘compete’ for a finite number of miRNAs, which essentially results in 
them regulating each other [245].  This theory has resulted from the discovery of many other 
functional non-coding RNAs (ncRNAs), which has shown the complexity of our ‘RNA-ome’, 
including the possibility that they interact in yet-to-be identified ways forming a complex 
network [245]. 
 
 
1.2.1.3.3 Regulation of key cancer-related pathways 
 
MiRNA dysregulation has been linked to the hallmarks of cancer as proposed by Hanahan 
and Weinberg; evasion of growth suppression, resisting apoptosis, induction of angiogenesis, 
invasion and metastasis [246]. They contribute to cancer development through regulation of 
the cell cycle, senescence and through their contribution to the DNA damage response 
network. 
 
 
1.2.1.3.3.1 Cell cycle and proliferation 
 
The role of miRNAs in controlling proliferation of cells has been well described in the 
literature, with many publications reporting the role of miRNA derangements in consequent 
cell cycle disruption and tumorigenesis [208].  MiRNAs can be oncogenes (usually if over-
expressed) by increasing entry and progression of the cell cycle or TSGs, as evidenced by 
their loss or decreased expression resulting in loss of cell cycle arrest and subsequent tumour 
formation.  A key example of this is the retinoblastoma pathway (pRb), which has been found 
to be affected in many human cancers and is responsible for repression of E2F transcription 
factor family [247].  These factors control the transcription of specific genes that play a role 
in cell-cycle progression [248].  If cyclin dependent kinases (CDKs) phosphorylate pRb, the 
repression is inhibited and E2Fs transcribe genes such as CDKs and cyclins which promote 
	   57	  
progression of the cell cycle [247].  It is these cylins and CDKs that are targets of growth-
suppressing miRNAs. 
 
Furthermore, positive regulators of the cell cycle including CDKs 1, 2 and 6 as well as 
cyclins D1, D3 and E1 have been shown to be targets of miRNAs, which help in G1 arrest 
[249]. 
 
Finally, anti-proliferative miRNA downregulation has been reported in response to growth-
promoting signaling pathways [250]. 
 
 
1.2.1.3.3.2 Regulation of senescence 
 
Senescence is essentially a barrier to tumour formation. It is the term given to an irreversible 
exit from the cell cycle and can result when cells reach a critical age due to shortening of 
telomere (replicative senescence) or prematurely, if cells are exposed to oxidative stress or 
DNA damage signaling (stress-induced senescence) [251].  Some miRNAs have been 
implicated as regulators of senescence pathways, including some which negatively regulate 
cell cycle progression.  MiR-let-7 is an example of this.  It’s target gene HMGA2 represses 
p16 and p19 (which are products of the INK4A locus that has been found to be mutated in 
many cancers).  Both p16 and p19 are critical inducers of senescence.  Another example 
includes the miR34 family, which have reportedly been found to be important regulators of 
cell senescence [238, 252].  
 
 
1.2.1.3.3.3 DNA damage response 
 
On a daily basis, cells of the human body are subjected to DNA damage through a variety of 
avenues; normal cellular metabolic processes, chemical and physical agents such as 
ultraviolet light, ionising radiation and environmental pollutants.  Recognition and repair of 
these DNA lesions or alterations in chromatin structure is the role of the DNA damage 
response (DDR) network, which is comprised of sensor proteins/kinases like ATM and ATR 
followed by CHK1 and CHK2 that, when activated, that trigger effector mechanisms such as 
the phosphorylation of target proteins like p53 thereby initiating a cellular response [253].  
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Cells can select from a range of DNA repair patterns to target the wide range of DNA-lesion 
types possible and effector mechanisms range from manipulation of gene expression to DNA 
repair to cell cycle or transcription arrest, to apoptosis [253-255]. Failure or impairment of 
the DDR mechanism in repairing DNA lesions or inducing apoptosis or senescence is thought 
to promote genetic instability and subsequent tumour development [253, 255]. MicroRNAs 
have been shown to play a critical role in the regulation of the DDR network via several 
mechanisms [208]: 
1. Sensors/mediators/transducers of DDR 
2. Effectors of DNA repair 
3. Effectors of apoptosis and cell cycle checkpoint 
 
The role of microRNA in the regulation of DDR-related genes and development of cancer is 
supported by several findings: 
1. Some of the differentially expressed microRNAs between tumour and healthy tissue have 
been shown to target DDR-related genes and regulate DDR processes.  For example, in 
glioblastoma multiforme tumour specimens miR-338-5p was found to be downregulated 
when compared to normal tissue.  When overexpressed, this microRNA has been associated 
with increased cell cycle arrest and apoptosis [256]. 
2. DDR-related microRNA expression patterns have differed in treatment-sensitive and 
treatment-resistant cells eg. miR-203 expression was found to be upregulated in colorectal 
cancer cell lines (HT29, HCT116 and RKO) that were resistant to chemotherapy agent 
oxaliplatin [257].  Furthermore, Mir-18a and miR-31 have been shown to be expressed in 
higher levels in radiation-sensitive cells, compared to their radiation-resistant counterparts 
[258, 259]. 
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Table 8: Examples of microRNAs that directly regulate the expression of DDR genes 
[97] 
 
 
1.2.1.4 Tissue microRNAs as molecular biomarkers 
 
Early studies on miRNAs indicated that profiling their expression was a relatively reliable 
way to classify different types of tumours.  Given their stability in formalin-fixed tissues and 
the fact that it was relatively easy to quantify their amounts, microRNAs expression analysis 
as a method for the diagnosis, measurement of clinical response and as an indicator of 
prognosis for a variety of pathological conditions including cancer became an area of great 
research interest [200, 208].  Just over a decade ago, microRNA expression levels were 
correlated with clinical outcomes; the first of which was expression of let-7, which was found 
to be decreased in patients with lung cancer and that within this group, these levels were 
associated with shorter survival post resection [260]. 
 
Subsequently, tissue microRNA expression levels have been shown in a variety of cancers, 
through the analysis of samples obtained either surgically (ie. during resection) or during 
biopsy [261]. 
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1.2.1.5 MircoRNAs in plasma/serum as biomarkers 
 
Recent studies have centred on seeking out potential diagnostic/prognostic biomarkers in 
human body fluids such as plasma/serum, saliva and urine in an attempt to explore these less 
invasive and more easily attainable samples.  Studies have demonstrated that microRNAs can 
be found in serum/plasma samples [262, 263].  MicroRNA’s in blood exist as part of 
microparticles and exosomes that prevent their degradation – an advantageous property for 
their potential use [262].  Other promising qualities includes the fact that they are easily 
extracted from serum and easily detectable by PCR methods. 
 
Deregulation of serum microRNA levels has since been identified in a number of human 
malignancies, including lymphoma, leukaemia, gastric, colorectal, breast, lung, prostate, 
hepatocellular, ovarian and pancreatic exocrine cancers [263]. 
 
The potential utility of microRNAs as serum/plasma biomarkers is not limited to cancers 
however; miRNA levels were found to be significantly lower in patients with rheumatoid 
arthritis (RA) and osteoarthritis (OA) compared to healthy controls (although the study 
reporting this did not distinguish between RA and OA) [264].  For such techniques to become 
widely used however, several challenges need to be met.  Firstly, large scale prospective 
studies investigating blood/body fluid miRNA levels and their correlation with 
clinicopathological data are required. Secondly, methods for serum/plasma extraction, 
storage, miRNAs for normalisation and statistical methods for result analysis will need to be 
standardised across the board [262, 263]. Nevertheless, this area appears to be a growing 
focus for research efforts at the present time. 
 
 
1.2.1.6 Therapeutic implications for microRNAs identification studies 
 
Given that dysregulated miRNA expression is thought to play a role in the pathogenesis of 
many disease-states, microRNAs have become potential therapeutic targets.  Essentially, the 
idea is to restore microRNA levels to ‘normal’. In instances where oncogenic miRNA 
expression has been upregulated resulting in a disease state, the use of anti-miRNAs to 
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reduce target miRNA levels (which can be done in various ways), either directly or 
indirectly.  Different classes of these agents exist, the main one of which are antagomirs 
which can essentially directly ‘silence’ miRNAs.  These small synthetic RNAs are 
complementary to the miRNA’s target, thereby making that target more resistant to 
degradation [227].  Others include the use of locked nucleic acids antisense oligonucleotides 
(LNAs), anti-miRNA oligonucleotides (AMOs), miRNA sponges, multiple-target anti-
miRNA antisense oligodeoxyribonucleotides (MTg-AMOs), miRNA-masking and 
nanoparticles [265].  Indirect methods to downregulate miRNA expression work to impair 
components of the miRNA biogenesis pathway (discussed previously).  One such way is 
through the use of tetracycline-inducible RNAs which downregulate Drosha or Dicer.  
However, this must be done in a very controlled way as those enzymes can affect all 
microRNAs [266].  
 
Alternatively, in many instances it is miRNA downregulation that results in the development 
of disease; for instance downregulation of miRNAs that have a tumour-suppressing effect.  In 
these cases, restoration of miRNA levels in specific tissues/cells is key.  Synthetic RNA 
‘duplexes’ (resembling siRNAs) are used.  These are recognized by the RISC complex and 
processed as if they were endogenous miRNA.  Challenges include the development of stable 
synthetic agents and effective tissue-specific delivery/administration methods.  One such 
example of successful application of this was reported by Kota et al.  In their 2009 study, 
they reported the use of an adeno-associated virus to deliver miR-26a in a mouse model of 
hepatocellular cancer (MiR-26a had previously been identified as being downregulated in 
hepatocellular carcinoma compared to normal liver tissue).  Administration of the virus 
resulted in reduced proliferation and apoptosis of cancer cells, effectively causing tumour 
regression [267]. 
 
 
1.2.2 MICRO RNAS IN PANCREATIC NEUROENDOCRINE TUMOURS  
 
Few studies to date, have investigated the role of miRNAs as diagnostic or prognostic 
markers in PNETs [268-270]. This is largely due to the relative rarity and heterogeneity of 
the disease, meaning that large study populations are difficult to obtain. Of the few studies 
miRNAs in PNETs, most have looked at miRNAs that distinguish between PNETs and 
normal pancreatic tissue.  MiR-193b expression has been reported as a discriminator of 
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PNETs in both tissue and serum from normal pancreatic tissue [269]. Over-expression of 
miR-103 and miR-107 and downregulation of miR-155 has also been reported in PNET 
tissue compared to normal tissue [268].   
 
Data on the association between miRNAs and biological behaviour of PNETs, however, is 
very limited.  In their 2015 study, Lee et al reported that high miR-196a expression was 
significantly correlated with advanced T stage, higher ki-67% index and higher mitotic 
counts.  Furthermore, higher miR-196a levels were associated with decreased disease-free 
and overall survival [270]. Another study demonstrated a strong association between 
increased miR-21 expression and higher ki67 index as well as the development of liver 
metastases [268]. Finally, miR-210 has been shown to correlate with metastatic disease and 
miR-642 with Ki67 index in a 2014 study by Thorns et al [269]. 
 
This limited body of literature has identified differential expression of microRNAs in tumour 
compared to normal tissue as well as between tumours exhibiting differing biological 
behaviour. There is promise in potentially identifying accurate and reliable prognostic 
biomarkers that will aid in predicting tumour behaviour and allow for the development of 
tailored therapeutic pathways for patients with PNETs. 
 
 
1.2.3 TECHNIQUES FOR MICRO RNA EXTRACTION AND ANALYSIS 
 
Significant advances in genomic technologies have allowed for the study of microRNA 
expression in cells, tissues and body fluids such as serum and urine.  Early techniques 
allowed only for microRNA extraction from fresh specimens, however advances have 
allowed for extraction from formalin-fixed, paraffin-embedded specimens. Profiling and 
quantification of microRNA expression can be performed using qRT-PCR techniques which 
allow for the detection and measurement of specific, individual microRNAs, microRNA 
cards or through a ‘discovery’ approach, which involves whole-genome analysis using RNA 
sequencing, microarrays and cloning techniques [271]. 
 
Once identified and quantified, in-silico analysis of identified miRNAs using computer 
databases which list microRNA sequences and validated mRNA targets can be used to 
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predict the functions and possible effects of identified miRNAs [271], thereby guiding further 
investigation.  
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2. AIMS 
 
The aims of this Master of Surgery were to contribute to the study of prognostic factors in 
patients with pancreatic neuroendocrine tumours.  More specifically, these were: 
 
A.  To perform retrospective collection of clinical, pathological and survival data on all 
patients who had undergone surgical resection for PNETs at Royal North Shore 
Hospital between 1992 and 2014; use this data to identify clinical, pathological 
prognostic factors and perform a survival analysis on these patients. 
 
B. To extract miRNA from formalin-fixed paraffin-embedded (FFPE) tumour specimens 
from a randomly selected subset of patients from this patient cohort and conduct a 
discovery study to identify and measure the expression of different miRNAs. 
 
C.  To identify whether common patterns of miRNA expression exist amongst PNETs  
 
D. To correlate miRNA expression profiles with clinicopathological and survival data 
collected on the patient cohort, including disease classification (benign vs malignant), 
development of metastases, disease-free and overall survival in an effort to identify 
those miRNAs that correlate with tumour behaviour/aggressiveness, thereby serving as 
prognostic indicators/biomarkers for this disease. 
 
 
. 
  
  
	   65	  
3. METHODS 
3.1 GENERAL DESCRIPTION 
Royal North Shore Hospital (RNSH) has been a major centre for pancreatic surgery for the 
last 25 years. In the last decade the number of pancreatic resections has increased from 20 per 
year to more than 60 per year. This study used tissue specimens from a cohort of patients 
with pancreatic neuroendocrine tumours who had undergone surgical resection. Specimens 
were obtained from tissue blocks of surgical specimens collected at the time of operation and 
stored in RNSH Pathology Department. A commercially available kit was used to extract 
microRNA and the expression of different miRNA in the extracted samples measured by 
using a microarray platform. MiRNAs of potential significance were identified by either their 
up or down regulation and their profiles correlated with already available survival data on the 
patient cohort. 
 
3.2 ETHICS APPROVAL 
 
Ethics approval for this study was obtained as a ‘Low Negligible Risk’ study from the 
Northern Sydney Local Health District Human Research Ethics Committee (NSLHD File 
Number 1310-350M, AURED HREC Reference Number LNR/13/HAWKE/354). 
 
 
3.3 PATIENT SELECTION 
 
All patients undergoing resection of PNETs at Royal North Shore Hospital and North Shore 
Private Hospitals (Sydney, Australia) between 1992 and 2014 were considered eligible for 
retrospective study inclusion. Patients with inadequate follow-up and insufficient tumour size 
for adequate sampling were excluded. 
 
Patients were divided into two groups based on whether their disease was locoregional only 
(defined as disease confined to the pancreas and/or locoregional lymph nodes*) (L), or 
whether they had distant metastases either at the time of surgery or during their postoperative 
follow-up (defined as metastasis of any organ/structure not considered locoregional) (DM). 
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* Locoregional lymph nodes were defined as per the recommended pathological 
classification of lymph node involvement by Washington et al (discussed in section 1.1.8.13).  
This included lymph nodes superior, inferior, anterior and posterior to the pancreas as well as 
hepatic artery, retroperitoneal and lateral aortic nodes. For tumours of the pancreatic head, 
infrapyloric, subpyloric and coeliac nodes were also considered regional lymph nodes while 
for body and tail tumours, pancreatico-lieno and splenic nodes were also classified as 
locoregional disease. 
 
 
3.4 PATHOLOGICAL, CLINICAL AND SURVIVAL DATA COLLECTION 
 
3.4.1 Pathological data 
 
Pathological data was obtained from existing reports from the Royal North Shore Hospital 
Pathology Department records.  These reports were created after initial histopathological 
examination of surgically-resected specimens, prior to specimens being fixed in formalin and 
embedded in paraffin. 
 
 
3.4.2 Clinical data  
 
Clinical data was obtained retrospectively from a prospectively maintained database. This 
database included: patient name, date of birth, date of operation, length of stay, operative 
information and morbidity data. 
 
 
3.4.3 Survival data 
 
Survival data was collected through examination of the patients’ paper and electronic records 
to determine dates of last review. Patient follow-up was conducted by clinical evaluation by 
the consultant surgeon who performed the initial procedure, assessment of serum 
chromogranin A and periodic CT and PET scans as indicated. Patients were followed 
postoperatively at 6 month intervals for the first five years, then annually thereafter. In the 
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instance of recurrent disease/discovery of distant metastases, decisions regarding future 
treatment were made after review at specialised neuroendocrine multidisciplinary team 
meetings. 
 
Disease-Free Survival (DFS) was defined as the time from initial surgical resection to the 
date of death (from any cause) or first evidence of recurrence (either locoregional or 
metastatic). Overall survival (OS) was defined as the time from initial surgical resection of 
primary tumour to the date of death (from any cause). Date of last review was used to 
calculate survival values.   
 
 
3.5 SPECIMEN COLLECTION, PREPARATION AND STORAGE 
 
All patients had resection with curative intent including enucleation (insulinoma only), 
pancreatic resection +/- regional lymph node clearance +/- limited liver resection for isolated 
metastasis as indicated. After examination by a pathologist, fresh surgically-resected 
specimens were formalin-fixed and paraffin-embedded (FFPE) and archived on-site in the 
Royal North Shore Hospital Department of Pathology.  
 
 
3.6 PREPARATION OF SAMPLES FOR MIRNA ANALYSIS 
 
Specimen shavings were prepared by a pathologist. Excess paraffin was trimmed off 
specimen block and two shavings of each specimen each of 5 micron thickness were 
microdissected and placed in a 1.5 mL Eppendorf tube after examination confirming the 
diagnosis of PNET. 
  
 
3.7 RNA EXTRACTION 
All patient data and specimens were de-identified at the commencement of the laboratory 
component of this study through the allocation of randomised identification numbers.  
The FFPE RNeasy Kit (Qiagen, Hilden, Germany) was used for extraction of total RNA 
according to the manufacturer’s instructions. 
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3.7.1 Preparation of buffers 
 
3.7.1.1 DNase I stock solution 
 
1500 Kunitz units of lysophilised DNase I was added to 550 µL of RNase-free water using 
supplied RNase-free needle and syringe. Solution was mixed by gentle inversion. 
 
 
3.7.1.2 Buffer RPE: 
 
44 ml of 100 % ethanol was added to a provided bottle containing 11 ml Buffer RPE 
concentrate.  Prior to each use, the reconstituted Buffer RPE was mixed by gently shaking. 
 
 
3.7.2 Purification of total RNA including miRNA from FFPE tissue sections 
 
All procedures were conducted at room temperature (15-25 degrees Celcius).  Temperature in 
the centrifuge was 24 degrees Celcius, at maximum speed (25,000 rcf). 
 
Workspace and equipment was wiped down with ‘RNaseZap’ RNase decontamination 
solution prior to commencing experiments. 
 
1. 160 µL of deparaffinisation solution was added to each specimen in individual 
Eppendorf tube, before vortexing vigorously for 10 seconds.  Tubes were then placed 
centrifuge briefly to bring sample to the bottom of the tube. 
2. Samples were incubated at 56 degrees Celcius for three minutes, then allowed to cool at 
room temperature 
3. 150 µL of buffer PKD solution was added to each sample and mixed by vortexing. 
4. Specimens were placed in a centrifuge for one minute at 11,000 x g ie. 11,000 rcf 
(10,000 rpm) 
5. 10 µL proteinase K was added to the lower clear phase and contents of tube was gently 
mixed by pipetting up and down 
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6. Samples were incubated at 56 degrees Celcius for 15 minutes, then transferred to 
another incubator set at 80 degrees Celcius for 15 minutes 
7. The lower, clear phase in each specimen tube was transferred into a new 1.5 mL 
microcentrifuge tube, the initial tube and remaining contents were discarded. 
8. New microcentrifuge tubes containing clear phase were incubated on ice for three 
minutes, then centrifuged for 15 minutes at 20,000 x g (13,500 rpm). 
9. Taking care not to disturb the pellet now present in each tube, the supernatant was 
transferred by pipette into a new microcentrifuge tube. 
10.  Approximate volume in each tube at this point was 15 µL. 1.5 µL of DNase Booster 
Buffer and 10 µL DNase stock solution was added to each tube and mixed by gentle 
inversion of the tube. Samples were briefly placed in a centrifuge in order to collect 
residual liquid from sides tube. 
11. Samples were incubated at room temperature (22 degrees Celcius) for 15 minutes. 
12. 320 µL of Buffer RBC was added to adjust binding conditions.  Resulting lysate was 
mixed thoroughly. 
13. 1120 µL of 200-proof ethanol was added to the sample and mixed by gentle pipetting 
before immediately proceeding to next step. 
14. 700 µL of each sample was placed into a supplied RNeasy MinElute spin column 
placed in a two millilitre collection tube. This was then placed in centrifuge at 8,000 x g 
(10,000 rpm). Flow-through collected in collection tube was discarded and collection 
tube was re-used for same specimen. 
15. The above step was repeated by adding 700 µL increments of each specimen to 
corresponding spin columns until all of the specimen had been passed through. 
16.  500 µL Buffer RPE was added to each spin column before centrifuging at 8,000 x g 
(10,000 rpm) for 15 seconds. Flow-through collected in collection was discarded. 
17.  Spin columns were placed in new two millilitre collection tubes.  Lids of spin columns 
were opened (to dry spin column membrane) and samples were centrifuged at full 
speed (20,238 x g) for five minutes.  Collection tubes containing follow-through were 
discarded. 
18. Spin columns were placed into final 1.5 ml collection tubes. 18 µL of RNase-free water 
was added to each spin column membrane.  
19. Lids were closed and columns placed into centrifuge at full speed (20,238 x g) for one 
minute. Spin columns were then discarded, leaving collection tubes containing final 
specimens. 
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Figure 2: Diagrammatic overview of RNA extraction procedure 
 
 
3.7.3 Assessment of RNA quality 
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A Nanodrop ND1000 Spectrophotometer (ThermoFisher Scientific, Waltham, Mass) was 
used to measure concentrations (A260), protein contamination (A260:A280 ratio) and 
contamination with organic compounds or buffer components (A260:A230 ratio) in extracted 
RNA samples using the following procedure: 
 
1.  Top and bottom of nanodrop machine specimen reservoir was cleaned with Kimtech 
wipe 
2. 2 µL of RNase free water was placed onto specimen reservoir 
3. Machine settings ‘ND1000’ and ‘nucleic acid’ were selected before clicking ‘ok’ 
4.  Sample type was then changed to ‘RNA-40’ 
5. ‘Blank’ was selected to create control, then measurement performed 
6. Specimen reservoir was cleaned with Kimtech wipe (top & bottom) 
7. 2 µL of next sample placed on specimen reservoir and measurement made 
8.  Steps 6-7 were repeated until all specimens had been read 
 
 
3.7.4 Specimen storage and handling 
 
Specimens were stored in a freezer at -80 degrees Celcius until transported to Exiqon in 
Denmark. They were transported in a container filled with dry ice by air by World Courier. 
The container was manually topped-up with dry ice periodically during transport. 
 
 
3.7.5 Preparation of slides for tissue microarray 
 
MiRNA microarray profiling was performed by Exiqon Services (Vedbaek, Denmark).  
 
 
3.7.5.1 Confirmation of RNA Quality 
 
Total RNA quality was first determined by Exiqon using an Agilent 2100 Bioanalyzer profile 
(Agilent, USA).  
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3.7.5.2 Labeling Protocol 
 
The miRCURY LNA microRNA Hi-Power Labeling Kit, Hy3TM/Hy5TM (Exiqon, 
Denmark) was used to Label 150ng each of total RNA from each sample with Hy3TM and 
reference with Hy5TM fluorescent label as follows:  
 
1.  All kit components were placed on ice to thaw for 15 minutes, mixed thoroughly by 
vortexing before briefly centrifuging. 
2. 0.25 µg of total RNA, 1 µL of Spike-in microRNA Kit v2, 0.5 µL of CIP buffer and 0.5 
µL of CIP enzyme were combined in an RNase-free microcentrifuge tube and mixed by 
pipetting up and down. 
3. Preparation was incubated at 37 degrees Celcius for 30 minutes using a PCR cycler 
with heated lid. 
4. Preparation was then incubated at 95 degrees Celcius for 5 minutes to stop the 
enzymatic reaction and denature the RNA, before snap cooling on ice for up to 15 
minutes. 
5. Preparation was briefly placed in the centrifuge to mix 
6. 3 µL of Hi-Power Labelling Buffer, 2 µL of DMSO and 1 µL of Hi-Power Labelling 
enzyme were added to the preparation 
7. 1.5 µL of appropriate Fluorescent label (Hy3 for samples and Hy5 for reference) was 
added to each microcentrifuge tube. 
8.  Reagents were mixed by pipetting up and down to thoroughly mix 
9. Preparation was incubated for 2 hours at 16 degrees Celsius using a PCR cycler with a 
heated lid out of light, then incubated at 65 degrees Celsius for 15 minutes to stop the 
labeling procedure. 
10. Hybridisation procedure was performed within 2 hours and samples were protected 
from light. 
 
 
3.7.5.3 Hybridisation Protocol 
 
Labeled samples were mixed in a pair-wise fashion before hybridization to the miRCURY 
LNA microRNA Array 7th Generation (Exiqon, Denmark) using a Tecan HS4800 
hybridization station (Tecan, Austria). This targeted all microRNAs for human, mouse and 
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rat registered in the miRBASE 18.0 and contained 3100 capture probes.  
 
1. Samples from the Hy3 and Hy5 labeling reactions were combined on ice in a pair-wise 
fashion 
2. 25 µL of hybridisation buffer was added to each sample, mixed by vortexing, then spun 
briefly in centrifuge. 
3. Samples were incubated at 95 degrees Celcius for 2 minutes to denature while being 
protected from light 
4.  Samples were ten placed on ice for up to 90 minutes, before being spun down briefly in 
centrifuge again 
5. Slides were loaded into hybridisation chambers and prewashed with buffer at 56 
degrees Celcius for 30 seconds to prime slide chamber 
6. Hybridisation chamber was flushed with 1 x Hybridisation buffer then diluted with 100 
µL of water 
7.  50 µL of target preparation was injected into hybridisation station followed by 10 µL 
diluted 1 x Hybridisation buffer to flush injection inlet. 
8. Samples were then incubated at 56 degrees Celcius for 16 hours, with ‘agitation’ set to 
‘medium’. 
9. Wash buffer A was used to wash specimens for 1 minute after 1 minute of soaking. 
This was repeated twice at 56 degrees Celcius 
10.  Wash buffer B was used to wash specimens for 1 minute after 1 minute of soaking. 
This was repeated twice at 23 degrees Celcius 
11. Wash buffer C was used to wash specimens for 1 minute after 1 minute of soaking. 
This was repeated twice at 23 degrees Celcius. 
12. Wash buffer C was used to wash specimens for a final 30 seconds at 23 degrees 
Celcius. 
13. Hybridisation station was set to drying mode and slides were dried for 5 minutes. 
 
 
3.7.6 Scanning and image analysis of microarray slides 
 
Microarray slides were then scanned using the Agilent G2565B Microarray Scanner System 
(Agilent Technologies, Inc., USA) in an ozone free environment (less than 2 ppb ozone) to 
prevent bleaching with ozone. Sensitivity was adjusted to 100% PMT. 
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Microarray image analysis was performed using ImaGene 9.0 data analysis software 
(BioDiscovery, Inc., USA). This software worked by placing a grid on top of the scanned 
array image and identifying which probe was located at each spot.  Signal intensity and 
surrounding background were quantified, then signals were background corrected and 
normalised using the quantile normalisation method. Median signal intensity obtained after 
image analysis from each spot and each channel were measured and normalized.  For each of 
the normalised datasets, the ratio between Hy3 and Hy5 channels was determined. 
 
 
3.7.7 Identification of candidate miRNAs of significance through fold-changes of 
significance 
 
For selection of potential microRNA candidates, mean log median ratios (LMRs), differences 
in LMRs and associated p-values between groups of samples were determined. MiRNAs of 
potential significance were identified by a fold change of greater than or equal to two and p-
value <0.05. All calculations for the microarray component of the study were performed by 
Exiqon in the software R/Bioconductor (mainly using the limma package). The volcano plot 
was created using Prim7 software whilst Rstudio was used to generate the heatmap for 
potential candidate miRNAs. 
  
 
3.7.8 Identification of miRNAs of candidate through miRNA target prediction tools 
 
Bioinformatic tools were used to predict putative gene targets for miRNAs differentially-
expressed to a statistically-significant degree. Several databases were used to minimise 
disconcordance and identify genuine miRNA targets.  These included TargetScan 
(www.targetscan.org), MiRBase (www.mirbase.org) and TarBase (www. 
http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index). The list of 
potential gene targets generated was searched for genes known to be implicated in PNET 
pathogenesis pathways, as determined by a literature search and stated in section 1.14. Target 
genes identified by all three databases (for each miRNA) were identified; these were 
considered final candidate miRNAs. 
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3.7.9 Statistical analysis of data and correlation with clinicopathological data 
 
Expression of candidate miRNAs was correlated with clinicopathological data using chi-
squared and students t-test. Relationship between MiRNA expression and survival was 
performed using Kaplan-Meier survival analysis.  Statistical analysis was performed using 
SPSS version 24 (IBM Corporation, NY, USA). 
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4. RESULTS 
 
4.1 CLINICOPATHOLOGICAL CHARACTERISTICS 
 
4.1.1 Age and sex 
 
37 patients (19 females and 18 males) met the inclusion criteria of having sufficient 
clinicopathological and complete follow-up data for this study (see Table 9).  
 
Across all patients, median age at resection was 59.8 years.  Median age at time of resection 
for patients who had or went on to develop distant metastases was 57.9 years. Patients with 
only locoregional disease had a higher median age of 59.8 years, however the difference 
between the two groups did not reach statistical significance (p = 0.167). As only patients 
with complete follow-up data were included, there was no loss to follow up. 
 
 
4.1.2 Surgical procedure 
 
21 patients underwent distal pancreatectomy; of these 12 underwent distal pancreatectomy 
plus splenectomy (six laparoscopic procedures) while one had a distal pancreatectomy plus 
splenectomy and liver resection (for a solitary metastasis). Thirteen patients underwent 
pancreaticoduodenectomy alone, one underwent pancreaticoduodenctomy plus extended right 
hepatectomy whilst another underwent pancreatectomy, right hemicolectomy, right 
hemihepatectomy and total gastrectomy for metastases. 
 
 
4.1.3 Familial versus Sporadic Disease 
 
Of the 37 patients, most had sporadic PNETs (34 patients), whilst three had PNETs 
associated with MEN1. 
 
 
4.1.4 Functional vs non-functional disease 
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Fourteen patients presented with symptoms indicating functional tumours, whilst 23 had non-
functional tumours. Of the patients with function tumours, eight had insulinomas, five 
gastrinomas and one had a glucagonoma. 
 
 
4.1.5 Histopathology 
 
4.1.5.1 Tumour grade 
 
With respect to tumour grade as reported by the WHO 2010 classification, patients had 
predominantly grade 1 tumours (n=22, 59%), followed by grade 2 tumours (n=14, 
38%).  Only one patient had a grade 3 tumour (3%) 
 
 
4.1.5.2 Ki 67 index 
 
Thirty-one patients had a ki67 index <2%, five patients had values between two and 
20% and one patient had an index greater than 20% at 40%. 
 
 
4.1.6 Locoregional vs metastatic disease 
 
In our study, 23 had locoregional disease only, while 14 patients had metastatic disease. Five 
patients had solitary liver metastases at initial presentation while nine developed distant 
metastases during the course of their follow-up. 
 
 
4.1.6.1 Comparison of clinicopathological characteristics between localised disease versus 
distant metastatic disease 
 
No difference between groups existed based upon sporadic versus syndromic tumours. 
Similarly, there was no statistically-significant difference between the two patient groups 
based on tumour type (functional versus non-functional) or subtype (NF-PNET, insulinoma, 
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gastrinoma or glucagonoma). Both vascular invasion and perineural invasion were present in 
greater proportions in the group that developed distant metastases and these differences were 
statistically significant. 
 
    Distant Metastases Locoregional p-value 
Mean age 
(range)   55.9 (32.8-79.0) 62.9 (41.0-87.1) 0.167 
Sex         
  Female 7 12   
  Male 7 11 0.898 
Aetiology         
  Sporadic 14 20   
  
Syndromic 
(MEN1) 0 3 0.159 
Type         
  Functional 3 11   
  Non-Functional 11 12 0.108 
Subtype         
  NFPNET 11 12   
  Insulinoma 2 6   
  Gastrinoma 0 5   
  Glucagonoma 1 0 0.101 
Perineural Invasion       
  Absent 11 23   
  Present 3 0 0.021 
Vascular 
Invasion         
  Absent 5 19   
  Present 9 4 0.004 
WHO 2010 
Grade        
  1 6 16   
  2 7 7   
  3 1 0 0.168 
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Table 9: Comparison of patient characteristics between L and DM groups 
 
 
Site N 
Liver only 9 
Liver and chest 2 
Liver, mediastinum and bone 1 
Liver and lymph node 1 
Liver and bone 1 
 
Table 10:  Location of metastases in DM group 
 
 
4.2 PATIENT SURVIVAL 
 
Of the 37 patients included in this study, five died over the during the course of follow up. 
Kaplan-Meier analysis showed that patients in the DM subgroup DM had poorer overall 
survival (OS) as compared to subgroup L with the difference reaching statistical significance 
(p = 0.046). See Figure 3. 
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Figure 3: Kaplan-Meier analysis comparing overall survival (OS) in patient groups 
 
 
4.3 RNA EXTRACTION 
Extraction of total RNA was successfully performed from all FFPE specimens.  Sample 
concentration and purity were confirmed as being satisfactory by measuring concentration 
(A260 value), protein contamination (A260:A280 ratio) and organic/buffer component 
contamination (A260:A230 ratio) in all specimens. The minimum quantity of 100 ng of total 
RNA (as requested by Exiqon) was obtained for each specimen. 
 
4.4 TISSUE MICROARRAY ANALYSIS 
 
MicroRNA profiling microarray was performed in all 37 tumours after samples were 
confirmed by Exiqon to be of satisfactory quality. 2097 microRNAs were identified across all 
specimens. 
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Figure 4: Overall heatmap showing relative expression of the top 50 microRNAs with 
the highest standard deviation across all samples.  Red indicates expression below the 
mean while green indicates expression above the mean expression value for each 
miRNA 
 
4.4.1 Differentially-expressed miRNAs between DM and L groups 
 
In total, 506 miRNAs with differential expression between the ‘Distant metastasis’ group and 
‘Locoregional’ group were identified. 265 of these miRNAs were downregulated in the DM 
group compared to the L group, whilst 241 were upregulated. Expression values of individual 
miNRAs are shown in Appendix 1 (Section 9). Of these, four miRNAs were differentially 
expressed to statistical significance. These included miR-3653 which was upregulated and 
miR-4417, miR-574-3p and miR-664b-3p which were all downregulated. Fold change and p-
values for these miRNAs are summarised in Table 11.  Differentially-expressed microRNAs 
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are graphically depicted as a volcano plot in Figure 6, in which significance (p-value) and 
fold-change on the y and x axes respectively. 
 
 
 
Figure 5: Heatmap showing relative expression of the four microRNAs (ie. those with 
the highest standard deviation) differentially expressed to a statistically-significant level 
between DM and L groups.  Red indicates expression below the mean (downregulation) 
while green indicates expression above the mean expression value (upregulation) for 
each miRNA 
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MicroRNA Fold change (log) P-value 
miR-3653 0.445 0.0207 
miR-4417 -0.442 0.0430 
miR-574-3p -0.377 0.0164 
miR-664b-
3p -0.252 0.0342 
 
Table 11: Fold change and p-values for microRNAs with significant differential 
expression between DM and L groups 
 
 
Figure 6: Volcano plot showing differentially expressed microRNAs between samples in 
DM groups. Blue dots represent miRNAs differentially expressed but not to statistical 
significance. Above the blue horizontal line are miRNAs downregulated (green dots) 
and upregulated (red dot) to a statistically-significant level 
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Mean expression of miR-3653 in the locoregional group was 5.85 and in the distant 
metastasis group was 6.30 ie. A greater degree of upregulation.  Student’s t-test revealed that 
this difference was statistically-significant (p=0.024).  
 
 
4.4.1.1	  Subgroup analysis 1: Recurrence after curative resection 
 
All patients received a curative resection (R0). Nine of these patient developed recurrent 
disease during follow up and mean expression of miR-3653 in these patients was 5.77, 
compared to 6.24 in patients who did not recur during follow up.  This difference was 
statistically significant (p=0.036). Overall survival was compared in these two groups as well, 
being lower in patients who had recurrence (121.5 months [standard error ±17.7]) compared 
those who did not (179.7 months [standard error ±7.7]), however this difference was not 
significant (p 0.77) 
 
 
4.4.1.2 Subgroup analysis 2: MiRNA-3653 expression in patients with locoregional 
disease only at surgery who went on to develop metastases 
 
Thirty-two patients had locoregional disease only at the time of surgical resection. Subgroup 
analysis performed on this group using student’s T-test was used to compare mean miR-3653 
expression in patient in patients who went on to develop metastasis during follow up (n=9) 
versus those who did not (n=23). Mean miR-3653 expression in patients who developed 
metastases was lower 5.78 (standard deviation (SD) ± 0.37), compared to 6.29 in patients 
with locoregional disease only (SD ± 0.64) .  This difference was statistically significant 
(p=0.024). 
 
 
4.5 CANDIDATE MICRORNA TARGET PREDICTION/IN-SILICO ANALYSIS 
 
The four potential candidate miRNAs with significantly differential expression between DM 
and L groups were further examined in terms of potential role in PNETs pathogenesis. Of the 
four, only miRNA-3653 was identified by all three databases as having a potential PNET-
related target; the ATRX gene.  The three other miRNAs with significantly differential 
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expression between DM and L groups had no targets related to current PNET pathways or 
were not present across the three databases used. 
 
 
4.6 CORRELATION BETWEEN MIR-3653 AND PATIENT SURVIVAL 
 
Mean survival in the DM group was 121.5 months and in the L group was 179.7 months.  
These values were correlated with mean expression of miRNA-3653 across both groups, 
however the difference did not reach statistical significance (p = 0.204). 
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5. DISCUSSION 
 
The purpose of this study was to identify miRNAs that could potentially serve as prognostic 
biomarkers in PNETs.  In our patient cohort, as expected, overall survival in patients with 
distant metastases was significantly shorter than patients with locoregional disease only and 
we identified several significantly differentially-expressed microRNAs between these two 
patient groups. Of these differentially expressed miRNAs, only MiR-3653 expression, which 
was upregulated in the distant metastasis group, had a possible target gene that has been 
implicated in the pathogenesis of PNETs; ATRX.  Furthermore, this target was predicted 
across all three target-gene databases searched.  These findings suggest that miR-3653 may 
be an indicator of a subset of patients with tumours of a more biologically aggressive nature 
and therefore could possibly serve as a biomarker for the development of metastatic disease, 
which in turn is associated with poorer prognosis. There are, however, several limitations to 
this study which mean that these conclusions cannot be drawn with confidence. 
 
Somatic mutations in the ATRX gene has been implicated in the development of a variety of 
cancer including PNETs, osteosarcomas, malignant phaeochromocytoma, gliomas and 
astrocytomas [43, 272-275].  This gene encodes a protein of the same name that acts as a 
transcription regulator and is a member of the SWI/SNF family of chromatin remodelling 
proteins [276]. ATRX protein is thought to play a role in chromatin stabilisation and 
remodelling by binding to histone H3.  Forming a complex with death-associated protein 6 
(DAXX), the ATRX-DAXX dimer recruits histone methyltransferase SUV39H which 
methylates lysine 9 and maintains chromatin in a state of repression[277]. It has also been 
shown to be involved in gene regulation at the interphase stage as well as in the segregation 
of chromosomes during mitosis [278] 
 
Patients with mutations in either ATRX or DAXX have been shown to exhibit the alternative 
lengthening of telomeres (ALT) phenotype [277, 279], in which telomere stabilisation 
facilitates tumour progression by preventing their shortening to a critical size at which 
apoptosis would otherwise ensue [280]. A recent study correlated DAXX/ATRX mutations 
and ALT activation with chromosomal instability in patients with PNETs. This study also 
found that DAXX/ATRX mutations and chromosomal instability were associated with larger 
primary tumours and late stage tumours, suggesting factors are important at later stage as a 
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‘transforming’ (as opposed to an initiating) changes in tumorigenesis [280]. Inactivating 
mutations in ATRX or DAXX have been found in 43% of patients with sporadic PNETs in a 
series of 68 patients[42].  This study, which included only grade 1 and 2 PNETS, reported 
mutation in the MEN1 gene in 43% of patients and mTOR pathway mutations in 14% of 
patients[42]. As ATRX is a predicted gene target of miR-3653, there is a possibility that 
upregulation of miR-3653 in patients with distant metastases and associated poorer overall 
survival seen in our study could act through this mechanism.  ATRX and DAXX mutations 
were found in only 6% of patients with MEN1 PNETs in another series [281]. 
 
The present study is, to our knowledge, the first to identify miR-3653 in association with 
PNETS. A review of the literature found only two other publications citing miR-3653. The 
first, by Lin et al, found that miR-3653 was an independent predictor of both recurrence-free 
survival and overall survival in a series of lung adenocarcinoma tissue specimens [282]. The 
other reported that MiR-3653 was upregulated in cervical cancer associated with human 
papillomavirus (HPV) compared to normal tissue [283]. To our knowledge, this is the first 
study which has raised the possibility that miR-3653 as miRNA of potential significance in 
PNETs and contributes to the small pool of miRNAs that have been suggested as possible 
biomarkers for biological behaviour in this disease.  
 
As previously mentioned, the findings of this study are, however, subject to several 
limitations. (1) Although this study has examined a relatively large series of patients given 
the rarity of PNETs, our sample size of 37 patients is still fairly small and therefore we are 
unable to make conclusions with certainty.  (2) The majority of patients (all except one) are 
classified as either grade 1 or 2 tumours (based on the WHO 2010 classification [37], thus the 
full spectrum of PNETs is not accurately represented. Whether miR-3653 expression 
correlates with tumour grade and the way in which tumour grade correlates with patient 
survival across all grades of PNET cannot be concluded from this study. At best, findings 
could be used to support existing prognostic tools through the development of a multivariate 
prognostic model. (3) Only tumour tissue was examined, thus relative expression of miRNAs 
between PNETs in different patients has been analysed rather than change in expression 
compared each individual patient’s ‘normal’ tissue. (4) Identified miRNAs with differential 
expression in this study are yet to be validated.  Further work is also needed to examine in 
more detail the relationship (if any) between miR-3653 and its suspected target gene ATRX.  
(5) The in-silico analysis performed searched only for a limited number of target genes; those 
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that had already been described in the literature as playing a role in PNET pathogenesis.  
Expanding the search to include genes with established significance in generalised cancer 
pathways could be performed and may yield further candidates of interest.  
 
Limited prognostic factors and poor response to treatment in the setting of metastatic disease 
have highlighted the need for biomarkers that predict prognosis in patient with PNETs. 
Identification of miRNAs associated with more aggressive tumour biology would enable 
identification of patients at a higher risk of disease recurrence after curative surgery and 
strategies closer surveillance and aggressive adjuvant treatment in these patients. 
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6. CONCLUSION 
 
In the present study, we successfully retrospectively collected clinical, pathological and 
survival data on our patient cohort. Survival analysis indicated that patients who developed 
metastatic disease had significantly poorer overall survival compared to patient who had 
localised disease only. Comparatively, between patients with metastatic disease versus 
locoregional disease only, there was no significant difference in clinical or pathological 
characteristics apart from vascular invasion, which was present in greater frequency in 
patients who developed metastases. From this cohort of patients, we also successfully 
performed RNA extraction from FFPE tissue, obtaining specimens of satisfactory quality and 
quantity for microarray analysis. 
 
With regards to miRNA expression patterns, we found significantly different expression of 
four microRNAs between patients with metastatic PNETs compared with those with 
locoregional disease only. Of these, miR-3653 was the only one to have a predicted gene 
target previously implicated in PNET development (ATRX) and therefore could possibly 
play a role in or be a biomarker for more aggressive tumour behaviour.  However, given the 
limitations of this study, such conclusions cannot be made with confidence and further work 
(beginning with validation) needs to be performed. 
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9. APPENDIX 
Appendix 1 - Microarray output data showing expression values of various miRNAs 
(relative to average values) in DM and L groups 
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